QUARTERLY REPORT

Q1 2020 — Quarterly report

Q1 2020PDF · 97 pages660 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 	10-Q
(Mark One)
☒ 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the Quarterly Period Ended 	March 31, 2020
OR
☐ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the transition period from 	to
Commission file number: 	001-16751
ANTHEM, INC.
(Exact name of registrant as specified in its charter)
Indiana 	35-2145715
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, 	Indiana 	46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 	331-1476
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading symbol(s) 	Name of each exchange on which registered
Common Stock, $0.01 par value 	ANTM 	New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. 	Yes 	☒ 	No 	☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 	Yes 	☒ 	No 	☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2
of the Exchange Act:
Large accelerated filer
☒
Accelerated filer 	☐
Non-accelerated filer
☐
Smaller reporting company 	☐
Emerging growth company 	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 	☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes 	☐ 	No 	☒
As of April 22, 2020, 	252,116,097 	shares of the Registrant’s Common Stock were outstanding.

-- 1 of 97 --

Anthem, Inc.
Quarterly Report on Form 10-Q
For the Period Ended 	March 31, 2020
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1. 	FINANCIAL STATEMENTS
Consolidated Balance Sheets as of March 31, 2020 (Unaudited) and December 31, 2019 	2
Consolidated Statements of Income (Unaudited) for the Three Months Ended March 31, 2020 and 2019 	3
Consolidated Statements of Comprehensive Income (Unaudited) for the Three Months Ended March 31, 2020 and 2019 	4
Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2020 and 2019 	5
Consolidated Statements of Shareholders’ Equity (Unaudited) for the Three Months Ended March 31, 2020 and 2019 	6
Notes to Consolidated Financial Statements (Unaudited) 	7
ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 	38
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 	54
ITEM 4. 	CONTROLS AND PROCEDURES 	54
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS 	54
ITEM 1A. 	RISK FACTORS 	54
ITEM 2. 	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 	56
ITEM 3. 	DEFAULTS UPON SENIOR SECURITIES 	56
ITEM 4. 	MINE SAFETY DISCLOSURES 	56
ITEM 5. 	OTHER INFORMATION 	56
ITEM 6. 	EXHIBITS 	57
SIGNATURES 	58
-1-

-- 2 of 97 --

PART I. FINANCIAL INFORMATION
ITEM 1. 	FINANCIAL STATEMENTS
Anthem, Inc.
Consolidated Balance Sheets
March 31,
2020
December 31,
2019
(In millions, except share data) 	(Unaudited)
Assets
Current assets:
Cash and cash equivalents 	$ 	5,345 	$ 	4,937
Fixed maturity securities (amortized cost of $20,211 and $19,021; allowance for credit losses of $51 and $0) 	19,881 	19,676
Equity securities 	570 	1,009
Premium receivables 	5,786 	5,014
Self-funded receivables 	2,613 	2,570
Other receivables 	2,926 	2,807
Other current assets 	4,135 	3,020
Total current assets 	41,256 	39,033
Long-term investments:
Fixed maturity securities (amortized cost of $489 and $487;
allowance for credit losses of $0 and $0) 	505 	505
Other invested assets 	4,181 	4,258
Property and equipment, net 	3,350 	3,133
Goodwill 	21,661 	20,500
Other intangible assets 	9,613 	8,674
Other noncurrent assets 	1,833 	1,350
Total assets 	$ 	82,399 	$ 	77,453
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Medical claims payable 	$ 	9,902 	$ 	8,842
Other policyholder liabilities 	3,252 	3,050
Unearned income 	947 	1,017
Accounts payable and accrued expenses 	5,058 	4,198
Short-term borrowings 	1,075 	700
Current portion of long-term debt 	1,603 	1,598
Other current liabilities 	5,202 	4,127
Total current liabilities 	27,039 	23,532
Long-term debt, less current portion 	19,005 	17,787
Reserves for future policy benefits 	754 	759
Deferred tax liabilities, net 	2,213 	2,227
Other noncurrent liabilities 	1,695 	1,420
Total liabilities 	50,706 	45,725
Commitment and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none 	— 	—
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
252,020,028 and 252,922,161 	3 	3
Additional paid-in capital 	9,338 	9,448
Retained earnings 	23,360 	22,573
Accumulated other comprehensive loss 	(1,008) 	(296)
Total shareholders’ equity 	31,693 	31,728
Total liabilities and shareholders’ equity 	$ 	82,399 	$ 	77,453

-- 3 of 97 --

See accompanying notes.
-2-

-- 4 of 97 --

Anthem, Inc.
Consolidated Statements of Income
(Unaudited)
Three Months Ended
March 31
(In millions, except per share data) 	2020 	2019
Revenues
Premiums 	$ 	25,517 	$ 	22,843
Product revenue 	2,344 	—
Administrative fees and other revenue 	1,587 	1,545
Total operating revenue 	29,448 	24,388
Net investment income 	254 	210
Net realized (losses) gains on financial instruments 	(24) 	78
Impairment losses on investments:
Total impairment losses on investments 	(101) 	(13)
Portion of impairment losses recognized in other comprehensive income 	44 	3
Impairment losses recognized in income 	(57) 	(10)
Total revenues 	29,621 	24,666
Expenses
Benefit expense 	21,489 	19,282
Cost of products sold 	1,984 	—
Selling, general and administrative expense 	3,781 	3,166
Interest expense 	194 	187
Amortization of other intangible assets 	83 	87
Loss (gain) on extinguishment of debt 	1 	(1)
Total expenses 	27,532 	22,721
Income before income tax expense 	2,089 	1,945
Income tax expense 	566 	394
Net income 	$ 	1,523 	$ 	1,551
Net income per share
Basic 	$ 	6.03 	$ 	6.03
Diluted 	$ 	5.94 	$ 	5.91
Dividends per share 	$ 	0.95 	$ 	0.80
See accompanying notes.
-3-

-- 5 of 97 --

Anthem, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
March 31
(In millions) 	2020 	2019
Net income 	$ 	1,523 	$ 	1,551
Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments 	(689) 	357
Change in non-credit component of impairment losses on investments 	(32) 	—
Change in net unrealized gains/losses on cash flow hedges 	3 	3
Change in net periodic pension and postretirement costs 	7 	3
Foreign currency translation adjustments 	(1) 	—
Other comprehensive (loss) income 	(712) 	363
Total comprehensive income 	$ 	811 	$ 	1,914
See accompanying notes.
-4-

-- 6 of 97 --

Anthem, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
March 31
(In millions) 	2020 	2019
Operating activities
Net income 	$ 	1,523 	$ 	1,551
Adjustments to reconcile net income to net cash provided by operating activities:
Net realized losses (gains) on financial instruments 	24 	(78)
Depreciation and amortization 	270 	289
Deferred income taxes 	57 	55
Share-based compensation 	67 	70
Changes in operating assets and liabilities:
Receivables, net 	(639) 	(753)
Other invested assets 	63 	(21)
Other assets 	(525) 	(125)
Policy liabilities 	692 	791
Unearned income 	(109) 	96
Accounts payable and other liabilities 	588 	(354)
Income taxes 	491 	115
Other, net 	13 	(6)
Net cash provided by operating activities 	2,515 	1,630
Investing activities
Purchases of investments 	(3,896) 	(6,069)
Proceeds from sale of investments 	2,728 	5,236
Maturities, calls and redemptions from investments 	597 	393
Purchases of subsidiaries, net of cash acquired 	(1,908) 	—
Purchases of property and equipment 	(204) 	(234)
Other, net 	(101) 	22
Net cash used in investing activities 	(2,784) 	(652)
Financing activities
Net proceeds from commercial paper borrowings 	905 	178
Proceeds from long-term borrowings 	300 	2
Repayments of long-term borrowings 	(52) 	(63)
Proceeds from short-term borrowings 	1,075 	2,710
Repayments of short-term borrowings 	(700) 	(2,760)
Repurchase and retirement of common stock 	(529) 	(294)
Cash dividends 	(240) 	(206)
Proceeds from issuance of common stock under employee stock plans 	44 	76
Taxes paid through withholding of common stock under employee stock plans 	(107) 	(78)
Other, net 	(17) 	6
Net cash provided by (used in) financing activities 	679 	(429)
Effect of foreign exchange rates on cash and cash equivalents 	(2) 	(1)
Change in cash and cash equivalents 	408 	548
Cash and cash equivalents at beginning of period 	4,937 	3,934
Cash and cash equivalents at end of period 	$ 	5,345 	$ 	4,482

-- 7 of 97 --

See accompanying notes.
-5-

-- 8 of 97 --

Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
(Unaudited)
Common Stock Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Total
Shareholders’
Equity	(In millions)
Number of
Shares
Par
Value
December 31, 2019 (audited) 	252.9 	$ 	3 	$ 	9,448 	$ 	22,573 	$ 	(296) 	$ 	31,728
Adoption of Accounting Standards Update No.
2016-13 (Note 2) 	— 	— 	— 	(35) 	— 	(35)
January 1, 2020 	252.9 	3 	9,448 	22,538 	(296) 	31,693
Net income 	— 	— 	— 	1,523 	— 	1,523
Other comprehensive loss 	— 	— 	— 	— 	(712) 	(712)
Repurchase and retirement of common stock 	(1.9) 	— 	(71) 	(458) 	— 	(529)
Dividends and dividend equivalents 	— 	— 	— 	(243) 	— 	(243)
Issuance of common stock under employee stock
plans, net of related tax benefits 	1.0 	— 	3 	— 	— 	3
Convertible debenture repurchases and
conversions 	— 	— 	(42) 	— 	— 	(42)
March 31, 2020 	252.0 	$ 	3 	$ 	9,338 	$ 	23,360 	(1,008) 	$ 	31,693
December 31, 2018 (audited) 	257.4 	$ 	3 	$ 	9,536 	$ 	19,988 	$ 	(986) 	$ 	28,541
Adoption of Accounting Standards Update No.
2016-02 (Note 2) 	— 	— 	— 	26 	— 	26
January 1, 2019 	257.4 	3 	9,536 	20,014 	(986) 	28,567
Net income 	— 	— 	— 	1,551 	— 	1,551
Other comprehensive income 	— 	— 	— 	— 	363 	363
Repurchase and retirement of common stock 	(1.1) 	— 	(71) 	(223) 	— 	(294)
Dividends and dividend equivalents 	— 	— 	— 	(206) 	— 	(206)
Issuance of common stock under employee stock
plans, net of related tax benefits 	1.1 	— 	69 	— 	— 	69
Convertible debenture repurchases and
conversions 	— 	— 	(52) 	— 	— 	(52)
March 31, 2019 	257.4 	$ 	3 	$ 	9,482 	$ 	21,136 	$ 	(623) 	$ 	29,998
See accompanying notes.
-6-

-- 9 of 97 --

Anthem, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
March 31, 2020
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. 	Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana
corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the
context otherwise requires.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 	42 	million 	medical members
through our affiliated health plans as of 	March 31, 2020. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group,
Individual, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or
HMOs; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit
products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial
services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of
specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology
benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products
& Services business, which administers the Federal Employees Health Benefits, or FEHB, Program.
We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. 	We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 	30 	counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through
arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous 	states across the
country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon Health, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply
Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing 	PBM services through our IngenioRx subsidiary. We are licensed to conduct
insurance operations in all 	50 	states and the District of Columbia through our subsidiaries.
2. 	Basis of Presentation and Significant Accounting Policies
Basis of Presentation: 	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted
accounting principles, or GAAP, for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for
annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 	2019 	Annual Report on Form
10-K, unless the information contained in those disclosures materially changed or is required by GAAP. Certain prior year amounts have been reclassified to
conform to the current year presentation. For additional information on prior year reclassifications, see Note 15, “Segment Information.” In the opinion of
management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the 	three
months ended 	March 31, 2020 	and 	2019 	have been recorded. The results of operations for the 	three 	months ended 	March 31, 2020 	are not necessarily indicative of
the results that may be expected for the full year ending 	December 31, 2020, or any other period. These unaudited consolidated financial statements should be read
in conjunction with our audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our 	2019 	Annual Report on Form 10-
K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and
liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
-7-

-- 10 of 97 --

period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these
translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: 	We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer
benefits and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled 	$221 	and 	$215 	at 	March 31, 2020 	and
December 31, 2019, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: 	Prior to 2020, our fixed maturities were evaluated for other-than-temporary impairment where credit related impairments were presented within
the other-than-temporary impairment losses recognized in our consolidated statements of income with an adjustment to the security’s amortized cost basis.
Effective January 1, 2020, if a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely
than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to
fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is
more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of
income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by
non-credit related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in
accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and
estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the
estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and
anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since
the purchase date of the securities. Such adjustments are reported within net investment income.
In accordance with the Financial Accounting Standards Board, or FASB guidance, the changes in fair value of our marketable equity securities are recognized
in our results of operations within net realized gains and losses on financial instruments.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash
surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest enables us to influence the operating or financial
decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The
equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and
losses are determined on the basis of the cost or amortized cost of the specific securities sold.
-8-

-- 11 of 97 --

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of
liabilities, we recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a
corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated
balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on
securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned
securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates
slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral
pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 	102% 	of the value of the
loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting
the investments to higher quality and shorter duration instruments.
Receivables: 	Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are
reported net of an allowance for doubtful accounts of 	$234 	and 	$237 	at March 31, 2020 and December 31, 2019, respectively. Self-funded receivables include
administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an allowance for doubtful accounts of
$55 	and 	$46 	at March 31, 2020 and 2019, respectively. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our
judgment regarding the ability to collect specific accounts.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades,
other government receivables and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of 	$282 	and
$242 	at March 31, 2020 and December 31, 2019, respectively, which is based on historical collection trends, future forecasts and our judgment regarding the
ability to collect specific accounts.
Revenue Recognition: 	For our non-fully-insured contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our
consolidated balance sheet at 	March 31, 2020. For the 	three 	months ended 	March 31, 2020, revenue recognized from performance obligations related to prior
periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue
expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to
undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: 	In November 2019, the FASB issued Accounting Standards Update No. 2019-11, 	Codification Improvements to
Topic 326, Financial Instruments - Credit Losses. In May 2019, the FASB issued Accounting Standards Update No. 2019-05, 	Financial Instruments - Credit
Losses (Topic 326): Targeted Transition Relief. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, 	Codification Improvements to Topic
326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. In November 2018, the FASB issued
Accounting Standards Update No. 2018-19, 	Codification Improvements to Topic 326, Financial Instruments - Credit Losses. These updates provide an option to
irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost and provide additional clarification and implementation
guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, 	Financial Instruments - Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments, 	or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13
introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments held at the reporting date based on
historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit
losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the
amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 requires a cumulative-effect adjustment to the opening balance
of retained earnings on the statement of financial position at the date of adoption and a prospective transition approach for debt securities for which an other-than-
temporary impairment had been recognized before the adoption date. The effect of a prospective transition approach is to maintain the same amortized cost basis
before and after the date of adoption. We adopted ASU 2016-13 on January 1, 2020, and
-9-

-- 12 of 97 --

recognized a cumulative-effect adjustment of 	$35 	to our opening retained earnings for credit related allowances on receivables. The adoption did not have an
impact on our consolidated statements of income or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-15, 	Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40):
Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract, or ASU 2018-15. The amendments in
ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the
arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments
also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and
statement of cash flows. We adopted ASU 2018-15 on January 1, 2020 using a prospective approach for all implementation costs incurred after the date of
adoption, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, 	Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the
Disclosure Requirements for Fair Value Measurement, 	or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure
requirements for fair value measurements. The amendments are effective for interim and annual periods beginning after December 15, 2019, with early adoption
permitted for either the entirety of ASU 2018-13 or only the provisions that eliminate or modify disclosure requirements. We early adopted the provisions that
eliminate and modify disclosure requirements, on a retrospective basis, effective in our 2018 Annual Report on Form 10-K. We adopted the new disclosure
requirements on January 1, 2020, on a prospective basis.
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, 	Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for
Goodwill Impairment, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which required a hypothetical
purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting
unit’s fair value. We adopted ASU 2017-04 on January 1, 2020, and the adoption did not have an impact on our consolidated financial position, results of
operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: 	In March 2020, the FASB issued Accounting Standards Update No. 2020-04, 	Reference Rate Reform (Topic
848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, or ASU 2020-04. ASU 2020-04 provides optional expedients and exceptions for
applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate, or
LIBOR, or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or
Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The provisions within ASU 2020-04 are
available until December 31, 2022, when the reference rate replacement activity is expected to have been completed. We are currently evaluating the provisions
within ASU 2020-04.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, 	Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, 	or
ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in ASC Topic 740. The amendments also clarify and amend
existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning after December 15, 2020, with early
adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable
guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We are currently evaluating the effects
the adoption of ASU 2019-12 will have on our consolidated financial statements.
In August 2018, the FASB issued Accounting Standards Update No. 2018-14, 	Compensation—Retirement Benefits - Defined Benefit Plans—General
(Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, or ASU 2018-14. The amendments in ASU 2018-
14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments
are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective
basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.
In August 2018, the FASB issued Accounting Standards Update No. 2018-12, 	Financial Services—Insurance (Topic 944): Targeted Improvements to the
Accounting for Long-Duration Contracts, 	or ASU 2018-12. The amendments in ASU
-10-

-- 13 of 97 --

2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-
duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and
update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and
add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments in
ASU 2018-12 will be effective for our interim and annual reporting periods beginning after December 15, 2021. The amendments related to the liability for future
policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest
period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of
the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of
ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 	2019 	Annual Report on Form 10-K that
had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3. 	Business Acquisition
Beacon Health Options, Inc.
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligns with our strategy to
diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions.
In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the preliminary fair value of Beacon’s
assets acquired and liabilities assumed, including identifiable intangible assets. The excess of the consideration transferred over the preliminary fair value of net
assets acquired resulted in preliminary goodwill of $1,049 	at March 31, 2020, all of which was allocated to our Other segment. Preliminary goodwill recognized
from the acquisition of Beacon primarily relates to the future economic benefits arising from the assets acquired and is consistent with our stated intentions and
strategy. Any additional payments or receipts of cash resulting from contractual purchase price adjustments or any subsequent adjustments made to the assets
acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill.
The preliminary fair value of the net assets acquired from Beacon includes 	$752 	of other intangible assets at March 31, 2020, which primarily consist of finite-
lived customer relationships with amortization periods ranging from 	9 	to 	21 	years. The results of operations of Beacon are included in our consolidated financial
statements within our Other segment for the period following February 28, 2020. The pro forma effects of this acquisition for prior periods were not material to our
consolidated results of operations.
4. 	Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. Our fixed maturity securities have been
negatively impacted by the significant market volatility that began in March 2020 due to the COVID-19 global health pandemic, or COVID-19 pandemic, and
other market related changes. Declines in fair value have increased the potential for material credit losses. We have established an allowance for credit loss and
recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review
policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value
may occur and additional material impairment losses on investments may be recorded in future periods.
-11-

-- 14 of 97 --

A summary of current and long-term fixed maturity securities, available-for-sale, at 	March 31, 2020 	and 	December 31, 2019 	is as follows:
Cost or
Amortized
Cost
Non-Credit
Component of
Impairment
Recognized in
Accumulated
Other
Comprehensive
Loss
Gross
Unrealized
Gains
Gross Unrealized Losses
Allowance For
Credit Losses
Estimated
Fair Value
Less than
12 Months
12 Months
or Greater
March 31, 2020
Fixed maturity securities:
United States Government securities 	$ 	450 	$ 	24 	$ 	— 	$ 	— 	$ 	— 	$ 	474 	$ 	—
Government sponsored securities 	369 	5 	(48) 	— 	— 	326 	—
States, municipalities and political
subdivisions 	4,768 	233 	(14) 	— 	— 	4,987 	—
Corporate securities 	9,609 	148 	(450) 	(44) 	(51) 	9,212 	(44)
Residential mortgage-backed
securities 	3,731 	93 	(95) 	(7) 	— 	3,722 	—
Commercial mortgage-backed
securities 	81 	1 	(3) 	(1) 	— 	78 	—
Other securities 	1,692 	6 	(97) 	(14) 	— 	1,587 	—
Total fixed maturity securities 	$ 	20,700 	$ 	510 	$ 	(707) 	$ 	(66) 	$ 	(51) 	$ 	20,386 	$ 	(44)
December 31, 2019
Fixed maturity securities:
United States Government securities 	$ 	524 	$ 	4 	$ 	(3) 	$ 	— 	$ 	— 	$ 	525 	$ 	—
Government sponsored securities 	136 	5 	— 	— 	— 	141 	—
States, municipalities and political
subdivisions 	4,592 	262 	(3) 	— 	— 	4,851 	—
Corporate securities 	8,870 	339 	(9) 	(15) 	— 	9,185 	(3)
Residential mortgage-backed
securities 	3,654 	87 	(6) 	(3) 	— 	3,732 	—
Commercial mortgage-backed
securities 	84 	2 	— 	— 	— 	86 	—
Other securities 	1,648 	21 	(3) 	(5) 	— 	1,661 	—
Total fixed maturity securities 	$ 	19,508 	$ 	720 	$ 	(24) 	$ 	(23) 	$ 	— 	$ 	20,181 	$ 	(3)
-12-

-- 15 of 97 --

For fixed maturity securities in an unrealized loss position at 	March 31, 2020 	and 	December 31, 2019, the following table summarizes the aggregate fair
values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:
Less than 12 Months 	12 Months or Greater
(Securities are whole amounts)
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
March 31, 2020
Fixed maturity securities:
United States Government securities 	1 	$ 	— 	$ 	— 	— 	$ 	— 	$ 	—
Government sponsored securities 	278 	224 	(48) 	1 	— 	—
States, municipalities and political subdivisions 	239 	509 	(14) 	3 	4 	—
Corporate securities 	2,773 	5,003 	(450) 	170 	176 	(44)
Residential mortgage-backed securities 	603 	1,182 	(95) 	63 	57 	(7)
Commercial mortgage-backed securities 	14 	29 	(3) 	3 	6 	(1)
Other securities 	520 	1,175 	(97) 	58 	142 	(14)
Total fixed maturity securities 	4,428 	$ 	8,122 	$ 	(707) 	298 	$ 	385 	$ 	(66)
December 31, 2019
Fixed maturity securities:
United States Government securities 	27 	$ 	250 	$ 	(3) 	2 	$ 	1 	$ 	—
Government sponsored securities 	14 	12 	— 	3 	1 	—
States, municipalities and political subdivisions 	114 	306 	(3) 	14 	11 	—
Corporate securities 	386 	558 	(9) 	224 	286 	(15)
Residential mortgage-backed securities 	321 	635 	(6) 	189 	237 	(3)
Commercial mortgage-backed securities 	1 	3 	— 	4 	8 	—
Other securities 	166 	415 	(3) 	113 	358 	(5)
Total fixed maturity securities 	1,029 	$ 	2,179 	$ 	(24) 	549 	$ 	902 	$ 	(23)
Below are discussions by security type for unrealized losses as of March 31, 2020:
United States Government securities: 	Unrealized losses on government sponsored securities have not been recognized into income because management does not
intend to sell and it is likely that management will not be required to sell these securities prior to their anticipated recovery. The decline in fair value is largely due
to changes in interest rates and other market conditions. We have evaluated the credit ratings of the securities and have determined that no allowance is necessary.
The fair value is expected to recover as the securities approach maturity.
Government sponsored securities: 	There were no material unrealized losses on investments in government sponsored securities. We have no intent to sell these
investments, and it is more likely than not that we will not be required to sell the investments before recovery of their amortized cost bases.
States, municipalities and political subdivisions: 	Unrealized losses on securities of states, municipalities and political subdivisions have not been recognized into
income because management does not intend to sell, and it is likely that management will not be required to sell these securities prior to their anticipated recovery,
and the decline in fair value is largely due to changes in interest rates and other market conditions. We have evaluated the credit ratings of the securities and have
determined that no allowance is necessary. The fair value is expected to recover as the securities approach maturity.
-13-

-- 16 of 97 --

Corporate securities: 	An allowance for credit losses on certain energy-related fixed maturity corporate securities has been determined based on qualitative and
quantitative factors including credit rating, default, industry condition and known information of the issuer along with other available market data. With multiple
risk factors present, these securities were reviewed for expected future cash flow to determine the portion of unrealized losses that were credit related and to record
an allowance for credit losses. No allowance for credit loss was required for the remaining corporate fixed maturity securities at March 31, 2020. Unrealized losses
on the remaining corporate securities have not been recognized into income because management does not intend to sell, and it is likely that management will not
be required to sell these securities prior to their anticipated recovery, and the decline in fair value is largely due to current market conditions relating to the
COVID-19 pandemic and tensions within the energy sector. We have evaluated each corporate security’s credit rating as well as industry risk factors associated
with the securities. At this time, no allowance has been deemed necessary. The issuers continue to make timely principal and interest payments on the bonds. The
fair value of these securities is expected to recover as they approach maturity.
Residential mortgage-backed securities: 	Unrealized losses on residential mortgage-backed securities have not been recognized into income because management
does not intend to sell, and it is likely that management will not be required to sell the securities prior to their anticipated recovery, and the decline in fair value is
largely due to changes in interest rates and other market conditions. We have evaluated the securities for any change in credit rating and have determined that no
allowance is necessary. The fair value is expected to recover as the securities approach maturity.
Commercial mortgage-backed securities: 	There were no material unrealized losses on investments in commercial mortgage-backed securities. We have no intent
to sell these investments, and it is more likely than not that we will not be required to sell the investments before recovery of their amortized cost bases.
Other securities: 	Unrealized losses on other securities have not been recognized into income because management does not intend to sell, and it is likely that
management will not be required to sell these securities prior to their anticipated recovery, and the decline in fair value is largely due to changes in interest rates
and other market conditions. Other securities largely consists of asset-backed securities. We have evaluated these securities for any change in credit rating and have
determined that no allowance is necessary. The fair value is expected to recover as the securities approach maturity.
The table below presents a roll-forward by major security type of the allowance for credit losses on fixed maturity securities available-for-sale held at period
end for the three months ended March 31, 2020:
Corporate Securities
Allowance for credit losses:
Beginning balance 	$ 	—
Additions for securities for which no previous expected credit losses were recognized 	51
Total allowance for credit losses 	$ 	51
The amortized cost and fair value of fixed maturity securities at 	March 31, 2020, by contractual maturity, are shown below. Expected maturities may differ
from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost
Estimated
Fair Value
Due in one year or less 	$ 	520 	$ 	511
Due after one year through five years 	5,730 	5,583
Due after five years through ten years 	6,035 	5,882
Due after ten years 	4,603 	4,610
Mortgage-backed securities 	3,812 	3,800
Total fixed maturity securities 	$ 	20,700 	$ 	20,386
-14-

-- 17 of 97 --

Proceeds from sales, maturities, calls or redemptions of fixed maturity securities and the related gross realized gains and gross realized losses for the 	three
months ended 	March 31, 2020 	and 	2019 	are as follows:
Three Months Ended
March 31
2020 	2019
Proceeds 	$ 	1,931 	$ 	1,468
Gross realized gains 	43 	18
Gross realized losses 	(20) 	(17)
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment
environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or
(v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or
amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at 	March 31, 2020 	and 	December 31, 2019 	is as follows:
March 31, 2020 	December 31, 2019
Equity securities:
Exchange traded funds 	$ 	245 	$ 	44
Fixed maturity mutual funds 	211 	643
Common equity securities 	32 	237
Private equity securities 	82 	85
Total 	$ 	570 	$ 	1,009
The gains and losses related to equity securities for the 	three 	months ended 	March 31, 2020 	and 2019 are as follows:
Three Months Ended March
31
2020 	2019
Net realized (losses) gains recognized on equity securities 	$ 	(50) 	$ 	79
Less: Net realized gains recognized on equity securities sold during the period 	(18) 	(21)
Unrealized (losses) gains recognized on equity securities still held at March 31 	$ 	(68) 	$ 	58
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as well as the cash
surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at
our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three
month lag due to the timing of when we receive financial information from the companies. Given the recent market volatility, there is a risk that the value of some
of these investments may decline in future periods.
Investment Income
At March 31, 2020 and December 31, 2019, accrued investment income totaled 	$166 	and 	$173, respectively. We recognize accrued investment income under
the caption “Other receivables” on our consolidated balance sheets.
-15-

-- 18 of 97 --

Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to 	$427 	and 	$351 	at 	March 31, 2020
and 	December 31, 2019, respectively. The value of the collateral represented 	103% 	of the market value of the securities on loan at each of 	March 31, 2020 	and
December 31, 2019. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a
corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in
the applicable investment category on our consolidated balance sheets.
The remaining contractual maturity of our securities lending agreements at 	March 31, 2020 	is as follows:
Overnight and
Continuous
Securities lending transactions
Cash 	$ 	354
United States Government securities 	69
Other securities 	4
Total 	$ 	427
The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value
appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the
loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the minimum
collateral level is set at 	102% 	of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is
subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.
5. 	Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions,
embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating
rates. The floating rates payable on all of our fair value hedges are benchmarked to LIBOR. Any amounts recognized for changes in fair value of these derivatives
are included in the captions “Other current or noncurrent assets” or “Other current or noncurrent liabilities” in our consolidated balance sheet.
Prior to 2020, we entered into a series of forward starting pay fixed interest rate swaps with the objective of reducing the variability of cash flows in the
interest payments on anticipated future financings. The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other
comprehensive loss, net of tax, was 	$259 	and $262 	at 	March 31, 2020 	and 	December 31, 2019, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.
-16-

-- 19 of 97 --

6. 	Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used
to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level Input 	Input Definition
Level I 	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II 	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the
measurement date.
Level III 	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the
measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value
in our consolidated balance sheets:
Cash equivalents: 	Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at
par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: 	Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available.
These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to
facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States Government securities and certain other asset-backed securities. For securities not actively traded, the
pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in
the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition,
we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are
often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We
also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation
methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit
spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: 	Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities,
quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are
available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated
based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity
securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital,
long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: 	Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained
primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements
and disclosures.
Derivatives: 	Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We
independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions.
Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a
master netting basis by counterparty.
-17-

-- 20 of 97 --

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at 	March 31, 2020 	and 	December 31, 2019
is as follows:
Level I 	Level II 	Level III 	Total
March 31, 2020
Assets:
Cash equivalents 	$ 	2,363 	$ 	— 	$ 	— 	$ 	2,363
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	474 	— 	474
Government sponsored securities 	— 	326 	— 	326
States, municipalities and political subdivisions, tax-exempt 	— 	4,987 	— 	4,987
Corporate securities 	— 	8,896 	316 	9,212
Residential mortgage-backed securities 	— 	3,720 	2 	3,722
Commercial mortgage-backed securities 	— 	78 	— 	78
Other securities 	— 	1,582 	5 	1,587
Total fixed maturity securities, available-for-sale 	— 	20,063 	323 	20,386
Equity securities:
Exchange traded funds 	245 	— 	— 	245
Fixed maturity mutual funds 	— 	211 	— 	211
Common equity securities 	2 	30 	— 	32
Private equity securities 	— 	— 	82 	82
Total equity securities 	247 	241 	82 	570
Securities lending collateral 	— 	426 	— 	426
Derivatives 	— 	49 	— 	49
Total assets 	$ 	2,610 	$ 	20,779 	$ 	405 	$ 	23,794
Liabilities:
Derivatives 	$ 	— 	$ 	(5) 	$ 	— 	$ 	(5)
Total liabilities 	$ 	— 	$ 	(5) 	$ 	— 	$ 	(5)
December 31, 2019
Assets:
Cash equivalents 	$ 	2,015 	$ 	— 	$ 	— 	$ 	2,015
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	525 	— 	525
Government sponsored securities 	— 	141 	— 	141
States, municipalities and political subdivisions, tax-exempt 	— 	4,851 	— 	4,851
Corporate securities 	— 	8,882 	303 	9,185
Residential mortgage-backed securities 	— 	3,730 	2 	3,732
Commercial mortgage-backed securities 	— 	86 	— 	86
Other securities 	— 	1,654 	7 	1,661
Total fixed maturity securities, available-for-sale 	— 	19,869 	312 	20,181
Equity securities:
Exchange traded funds 	44 	— 	— 	44
Fixed maturity mutual funds 	— 	643 	— 	643
Common equity securities 	206 	31 	— 	237
Private equity securities 	— 	— 	85 	85
Total equity securities 	250 	674 	85 	1,009
Securities lending collateral 	— 	353 	— 	353
Derivatives 	— 	23 	— 	23
Total assets 	$ 	2,265 	$ 	20,919 	$ 	397 	$ 	23,581
Liabilities:
Derivatives 	$ 	— 	$ 	(1) 	$ 	— 	$ 	(1)
Total liabilities 	$ 	— 	$ 	(1) 	$ 	— 	$ 	(1)

-- 21 of 97 --

-18-

-- 22 of 97 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the 	three months ended
March 31, 2020 	and 	2019 	is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other
Securities
Equity
Securities 	Total
Three Months Ended March 31, 2020
Beginning balance at January 1, 2020 	$ 	303 	$ 	2 	$ 	7 	$ 	85 	$ 	397
Total losses:
Recognized in net income 	(2) 	— 	— 	(6) 	(8)
Recognized in accumulated other comprehensive loss 	(10) 	— 	— 	— 	(10)
Purchases 	26 	— 	— 	12 	38
Sales 	(3) 	— 	— 	(9) 	(12)
Settlements 	(11) 	— 	(2) 	— 	(13)
Transfers into Level III 	13 	— 	— 	— 	13
Ending balance at March 31, 2020 	$ 	316 	$ 	2 	$ 	5 	$ 	82 	$ 	405
Change in unrealized losses included in net income related to assets still held at March 31,
2020 	$ 	— 	$ 	— 	$ 	— 	$ 	(7) 	$ 	(7)
Three Months Ended March 31, 2019
Beginning balance at January 1, 2019 	$ 	287 	$ 	6 	$ 	17 	$ 	313 	$ 	623
Total (losses) gains:
Recognized in net income 	(1) 	— 	— 	(2) 	(3)
Recognized in accumulated other comprehensive loss 	2 	— 	— 	— 	2
Purchases 	33 	— 	2 	7 	42
Sales 	(1) 	— 	— 	(21) 	(22)
Settlements 	(21) 	— 	(1) 	— 	(22)
Transfers into Level III 	— 	— 	3 	— 	3
Transfers out of Level III 	(2) 	— 	(7) 	— 	(9)
Ending balance at March 31, 2019 	$ 	297 	$ 	6 	$ 	14 	$ 	297 	$ 	614
Change in unrealized gains included in net income related to assets still held at March 31,
2019 	$ 	— 	$ 	— 	$ 	— 	$ 	(2) 	$ 	(2)
There were no individually material transfers into or out of Level III during the 	three 	months ended 	March 31, 2020 	or 	2019.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but
are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Beacon
on February 28, 2020. The preliminary values of net assets acquired in our acquisition of Beacon and resulting goodwill and other intangible assets were recorded
at fair value primarily using Level III inputs. The majority of Beacon’s assets acquired and liabilities assumed were recorded at their carrying values as of
the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The preliminary fair values of goodwill and
other intangible assets acquired in our acquisition of Beacon were internally estimated based on the income approach. The income approach estimates fair value
based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows
and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisition of Beacon described above, there were
no material assets or liabilities measured at fair value on a nonrecurring basis during the 	three 	months ended 	March 31, 2020 	or 	2019.
-19-

-- 23 of 97 --

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices
in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are
estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value
involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or
lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each
security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the
reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices
received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury
personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes
procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted
market prices obtained from the pricing services during the 	three 	months ended 	March 31, 2020 	or 	2019.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair
values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated
balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial
instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our
underlying economic value.
The carrying amounts for cash, accrued investment income, premium receivables, self-funded receivables, other receivables, income taxes receivable/payable,
unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities
approximate fair value because of the short term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our
consolidated balance sheets:
Other invested assets: 	Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as
well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled
corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance
policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: 	The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market
prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt – senior revolving credit facility: 	The carrying amount for the senior revolving credit facility approximates fair value, and is based on the
current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt – commercial paper: 	The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest
rates at market value.
Long-term debt – senior unsecured notes and surplus notes: 	The fair values of our notes are based on quoted market prices in active markets for the same or
similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and
remaining maturities.
-20-

-- 24 of 97 --

Long-term debt – convertible debentures: 	The fair value of our convertible debentures is based on the quoted market price in the active private market in
which the convertible debentures trade.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at
March 31, 2020 	and 	December 31, 2019 	is as follows:
Carrying
Value
Estimated Fair Value
Level I 	Level II 	Level III 	Total
March 31, 2020
Assets:
Other invested assets 	$ 	4,181 	$ 	— 	$ 	— 	$ 	4,181 	$ 	4,181
Liabilities:
Debt:
Short-term borrowings 	1,075 	— 	1,075 	— 	1,075
Senior revolving credit facility 	300 	— 	300 	— 	300
Commercial paper 	1,305 	— 	1,305 	— 	1,305
Notes 	18,867 	— 	20,343 	— 	20,343
Convertible debentures 	136 	— 	680 	— 	680
December 31, 2019
Assets:
Other invested assets 	$ 	4,258 	$ 	— 	$ 	— 	$ 	4,258 	$ 	4,258
Liabilities:
Debt:
Short-term borrowings 	700 	— 	700 	— 	700
Commercial paper 	400 	— 	400 	— 	400
Notes 	18,840 	— 	20,470 	— 	20,470
Convertible debentures 	145 	— 	904 	— 	904
7. 	Income Taxes
During the 	three months ended March 31, 2020 	and 	2019, we recognized income tax expense of 	$566 	and 	$394, respectively, which represent effective tax
rates of 	27.1% 	and 	20.3%, respectively. The 	increase 	in our effective income tax rate was primarily due to the reinstatement of the non-tax deductible Health
Insurance Provider Fee, or HIP Fee, for 2020.
Income taxes payable totaled 	$159 	at March 31, 2020. Income taxes receivable totaled 	$335 	at 	December 31, 2019. We recognize the income tax payable as a
liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance
sheets.
-21-

-- 25 of 97 --

8. 	Retirement Benefits
The components of net periodic benefit credit included in our consolidated statements of income for the 	three months ended March 31, 2020 	and 	2019 	are as
follows:
Pension Benefits 	Other Benefits
Three Months Ended
March 31
Three Months Ended
March 31
2020 	2019 	2020 	2019
Interest cost 	$ 	12 	$ 	16 	$ 	3 	$ 	4
Expected return on assets 	(40) 	(34) 	(6) 	(5)
Recognized actuarial loss 	6 	4 	— 	—
Settlement loss 	5 	2 	— 	—
Amortization of prior service credit 	— 	— 	(2) 	(3)
Net periodic benefit credit 	$ 	(17) 	$ 	(12) 	$ 	(5) 	$ 	(4)
For the year ending 	December 31, 2020, no material contributions are expected to be necessary to meet the Employee Retirement Income Security Act of
1974, as amended, or ERISA, required funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for
income tax purposes. No contributions were made to our retirement benefit plans during the 	three months ended March 31, 2020 	and 	2019.
9. 	Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the 	three months
ended March 31, 2020 	is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Gross medical claims payable, beginning of period 	$ 	3,039 	$ 	5,608 	$ 	— 	$ 	8,647
Ceded medical claims payable, beginning of period 	(14) 	(19) 	— 	(33)
Net medical claims payable, beginning of period 	3,025 	5,589 	— 	8,614
Business combinations and purchase adjustments 	— 	141 	198 	339
Net incurred medical claims:
Current period 	6,090 	15,010 	130 	21,230
Prior periods redundancies 	(293) 	(407) 	— 	(700)
Total net incurred medical claims 	5,797 	14,603 	130 	20,530
Net payments attributable to:
Current period medical claims 	3,908 	9,698 	138 	13,744
Prior periods medical claims 	1,875 	4,234 	— 	6,109
Total net payments 	5,783 	13,932 	138 	19,853
Net medical claims payable, end of period 	3,039 	6,401 	190 	9,630
Ceded medical claims payable, end of period 	37 	23 	— 	60
Gross medical claims payable, end of period 	$ 	3,076 	$ 	6,424 	$ 	190 	$ 	9,690
Activity in the Other segment resulted from our acquisition of Beacon.
At 	March 31, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty
Business was 	$94, 	$763 	and 	$2,182 	for the claim years 2018 and prior, 2019 and 2020, respectively.
-22-

-- 26 of 97 --

At 	March 31, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was 	$63,
$885 	and 	$5,453 	for the claim years 2018 and prior, 2019 and 2020, respectively.
At March 31, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was 	$0, 	$0 	and 	$190 	for the
claim years 2018 and prior, 2019 and 2020, respectively.
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the 	three months
ended March 31, 2019 	is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Gross medical claims payable, beginning of period 	$ 	2,586 	$ 	4,680 	$ 	— 	$ 	7,266
Ceded medical claims payable, beginning of period 	(10) 	(24) 	— 	(34)
Net medical claims payable, beginning of period 	2,576 	4,656 	— 	7,232
Net incurred medical claims:
Current period 	6,053 	12,741 	— 	18,794
Prior periods redundancies 	(197) 	(258) 	— 	(455)
Total net incurred medical claims 	5,856 	12,483 	— 	18,339
Net payments attributable to:
Current period medical claims 	3,898 	8,265 	— 	12,163
Prior periods medical claims 	1,766 	3,648 	— 	5,414
Total net payments 	5,664 	11,913 	— 	17,577
Net medical claims payable, end of period 	2,768 	5,226 	— 	7,994
Ceded medical claims payable, end of period 	8 	26 	— 	34
Gross medical claims payable, end of period 	$ 	2,776 	$ 	5,252 	$ 	— 	$ 	8,028
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 	2020 	are as follows:
Three Months Ended
March 31, 2020
Three Months Ended
March 31, 2019
Net incurred medical claims:
Commercial & Specialty Business 	$ 	5,797 	$ 	5,856
Government Business 	14,603 	12,483
Other 	130 	—
Total net incurred medical claims 	20,530 	18,339
Quality improvement and other claims expense 	959 	943
Benefit expense 	$ 	21,489 	$ 	19,282
-23-

-- 27 of 97 --

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the
consolidated balance sheet, as of 	March 31, 2020, is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Net medical claims payable, end of period 	$ 	3,039 	$ 	6,401 	$ 	190 	$ 	9,630
Ceded medical claims payable, end of period 	37 	23 	— 	60
Insurance lines other than short duration 	— 	212 	— 	212
Gross medical claims payable, end of period 	$ 	3,076 	$ 	6,636 	$ 	190 	$ 	9,902
10. 	Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At 	March 31, 2020 	and 	December 31, 2019, we had 	$18,842 	and 	$18,815,
respectively, outstanding under these notes.
We have an unsecured surplus note with an outstanding principal balance of 	$25 	at both 	March 31, 2020 	and 	December 31, 2019.
We have a senior revolving credit facility, or the 5-Year Facility, with a group of lenders for general corporate purposes. The 5-Year Facility provides credit
up to 	$2,500 	and matures in June 2024. We also have a 364-day senior revolving credit facility, or 364-Day Facility, with a group of lenders for general corporate
purposes, which provides for credit in the amount of 	$1,000 	and matures in June 2020. 	Our ability to borrow under these credit facilities is subject to compliance
with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain
circumstances set forth in the applicable credit agreement. 	As of March 31, 2020, our debt-to-capital ratio, as defined and calculated under the credit facilities, was
40.6%. We do not believe the restrictions contained in any of our credit facility covenants materially affect our financial or operating flexibility. As of March 31,
2020, we were in compliance with all of the debt covenants under these credit facilities. 	There were no amounts outstanding under the 364-Day Facility at any time
during the 	three months ended 	March 31, 2020 or the year ended 	December 31, 2019. At March 31, 2020 and December 31, 2019, 	$300 	and 	$0, respectively, were
outstanding under our 5-Year Facility. We repaid the 	$300 	outstanding on the 5-Year Facility on April 23, 2020.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit, or the Subsidiary Credit Facilities, with separate lenders for general
corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to 	$500. At 	March 31, 2020 	and 	December 31, 2019, 	$300 	and 	$50,
respectively, were outstanding under our Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to 	$3,500, the proceeds of which may be used for general corporate purposes. At 	March 31, 2020 	and
December 31, 2019, we had 	$1,305 	and 	$400, respectively, outstanding under this program.
We have outstanding senior unsecured convertible debentures due 2042, or the Debentures, which are governed by an indenture between us and The Bank of
New York Mellon Trust Company, N.A., as trustee, or the indenture. We have accounted for the Debentures in accordance with the FASB cash conversion
guidance for debt with conversion and other options. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) has
been bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. During the 	three months ended
March 31, 2020, 	$13 	aggregate principal amount of the Debentures were surrendered for conversion by certain holders in accordance with the terms and provisions
of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of 	$52. We recognized a loss of 	$1 	on the
extinguishment of debt related to the Debentures, based on the fair values of the debt on the conversion settlement dates.
-24-

-- 28 of 97 --

The following table summarizes at 	March 31, 2020 	the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount 	$ 	202
Unamortized debt discount 	$ 	64
Net debt carrying amount 	$ 	136
Equity component carrying amount 	$ 	73
Conversion rate (shares of common stock per $1,000 of principal amount) 	13.9862
Effective conversion price (per $1,000 of principal amount) 	$ 	71.4990
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal
Home Loan Bank of Atlanta, or collectively, the FHLBs. As a member, we have the ability to obtain short-term cash advances, subject to certain minimum
collateral requirements. We had 	$775 	and 	$650 	in outstanding short-term borrowings from the FHLBs at 	March 31, 2020 	and 	December 31, 2019, respectively,
with fixed interest rates of 	0.679% 	and 	1.664%, respectively.
All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.
11. 	Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff
or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged
damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we
have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can
reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether
any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with
respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess
of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented,
(ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the
class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the
plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for
which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of
established reserves is, in the aggregate, from 	$0 	to approximately 	$800 	at 	March 31, 2020. This estimated aggregate range of reasonably possible losses is based
upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue plans, across
the country. The cases were consolidated into a single, multi-district proceeding captioned 	In re Blue Cross Blue Shield Antitrust Litigation 	that is pending in the
United States District Court for the Northern District of Alabama, or the Court. Generally, the suits allege that the BCBSA and the Blue plans have conspired to
-25-

-- 29 of 97 --

horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on
acquisitions rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act, or Sherman Act, and
related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers, and actions filed in twenty-eight
states have been consolidated into the multi-district proceeding.
In response to cross motions for partial summary judgment by plaintiffs and defendants, the Court issued an order in April 2018 determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program
and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine
issues of material fact as to whether defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. No dates have
been set for either the final pretrial conferences or trials in these actions. In March 2019, the Court issued a Fourth Amended Scheduling Order requiring that
briefing on motions for class certification and related expert reports, merits and damages expert reports, and certain dispositive motions occur in 2019. In April
2019, plaintiffs filed their motions for class certification in conjunction with their supporting expert reports. Defendants filed their motions to exclude plaintiffs’
experts, as well as their opposition to plaintiffs’ motions for class certification, in July 2019. The case has been stayed by the court until further notice.
We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross), or BCC, was named as a defendant in a California
taxpayer action filed in Los Angeles County Superior Court, captioned 	Michael D. Myers v. State Board of Equalization, et al. 	This action was brought under a
California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law.
Plaintiff contends that BCC, a licensed Health Care Service Plan, or HCSP, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer”
under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax, or GPT, calculated as 	2.35% 	on gross premiums. As
a licensed HCSP, BCC has paid the California Corporate Franchise Tax, or CFT, the tax paid by California businesses generally. Plaintiff contends that BCC must
pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC to pay GPT back taxes,
interest, and penalties for the eight-year period prior to the filing of the complaint.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. We filed a writ of
mandate in the California Court of Appeal. Although the California Court of Appeal initially accepted our writ, it later indicated that it would not hear the issues
raised by our writ until the case concludes in the Superior Court. The Superior Court postponed the March 2020 trial date to July 2020. The parties are currently
engaged in discovery. Because GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los
Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC
eventually be determined to be subject to the GPT for the tax periods at issue in the litigation. BCC intends to vigorously defend this suit; however, its ultimate
outcome cannot be presently determined.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc., or Express Scripts, our vendor at the time for PBM services, captioned 	Anthem, Inc. v. Express
Scripts, Inc., in the U.S. District Court for the Southern District of New York. The lawsuit seeks to recover over 	$14,800 	in damages for pharmacy pricing that is
higher than competitive benchmark pricing under the agreement between the parties, or the ESI PBM Agreement, over 	$158 	in damages related to operational
breaches, as well as various declarations under the ESI PBM Agreement between the parties, including that Express Scripts: (i) breached its obligation to negotiate
in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM
Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive
benchmark pricing, for one year following any termination.
-26-

-- 30 of 97 --

Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI
PBM Agreement; and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing
under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we
have been unjustly enriched by its payment of 	$4,675 	at the time we entered into the ESI PBM Agreement. In March 2017, the court granted our motion to dismiss
Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining
claims are for breach of contract and declaratory relief. The period of time for completing discovery has been extended to August 2020 due to the recent outbreak
of COVID-19. We intend to vigorously pursue our claims and defend against any counterclaims, which we believe are without merit; however, the ultimate
outcome cannot be presently determined.
In re Express Scripts/Anthem ERISA Litigation
We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a
single multi-district lawsuit captioned 	In Re Express Scripts/Anthem ERISA Litigation, 	in the U.S. District Court for the Southern District of New York. The
consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants in or beneficiaries of any ERISA or non-
ERISA healthcare plan from December 1, 2009 to December 31, 2019 in which we provided prescription drug benefits through the ESI PBM Agreement and paid
a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under
ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’
pricing under the ESI PBM Agreement and (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher
pricing in the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with respect to the non-ERISA members, by
negotiating and entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and
Express Scripts jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains,
injunctive relief, attorney’s fees and costs and interest.
In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of
appeal with the United States Court of Appeals for the Second Circuit, which was heard in October 2018 but has not yet been decided. We intend to vigorously
defend this suit; however, its ultimate outcome cannot be presently determined.
Cigna Corporation Merger Litigation
In July 2015, we and Cigna Corporation, or Cigna, announced that we entered into the Cigna Agreement and Plan of Merger, or Cigna Merger Agreement,
pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice, or DOJ, along with certain state attorneys
general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia, or District Court, seeking to block the merger. In February 2017, Cigna
purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery, or Delaware Court, seeking
damages, including the 	$1,850 	termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of
the Cigna Merger Agreement was lawful, among other claims, which is captioned 	Cigna Corp. v. Anthem Inc.
Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from
terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned
Anthem Inc. v. Cigna Corp. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked
the merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to Cigna a
notice terminating the Cigna Merger Agreement.
In the Delaware Court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court held closing argument in
November 2019 and took the matter under consideration. In February 2020, the Delaware Court requested supplemental briefing which has been submitted. We
believe Cigna’s allegations are without merit and we intend to vigorously pursue our claims and defend against Cigna’s allegations; however, the ultimate outcome
of our litigation with Cigna cannot be presently determined.
-27-

-- 31 of 97 --

In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned 	Henry Bittmann, Derivatively, et al.
v. Joseph R Swedish, et al., purportedly on behalf of us and our shareholders against certain current and former directors and officers alleging breaches of fiduciary
duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the
outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.
Medicare Risk Adjustment Litigation
Beginning in December 2016, the DOJ issued civil investigative demands to us to discover information about our retrospective chart review and risk
adjustment programs under Parts C and D of the Medicare program. We understand the DOJ is investigating the programs of other Medicare Advantage health
plans, along with providers and vendors. In March 2020, the DOJ filed a civil lawsuit against Anthem, Inc. in U.S. District Court for the Southern District of New
York in a case captioned 	United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we
submitted to the Centers for Medicare and Medicaid Services, or CMS, for risk-adjustment purposes under Medicare Part C and knowingly failed to delete
inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on
inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. We have
until the end of May 2020 to respond. We intend to vigorously defend this suit; however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices (unrelated to our retrospective chart review program) at
CareMore Health Plans, Inc., or CareMore one of our California subsidiaries and HealthSun Health Plans, Inc., or HealthSun, one of our Florida subsidiaries. Our
CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation focuses
on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-
disclosed the existence of both investigations to CMS, and the Criminal Division of the DOJ, which then initiated an investigation. We are cooperating with that
investigation. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare
representation provisions, based on the conduct discovered during our investigation. We are in active litigation with one group of sellers regarding part of the
escrowed funds in a case captioned 	LPPAS Representative, LLC v. ATH Holding Company, LLC 	in the Delaware Court.
Cyber Attack Regulatory Proceedings and Litigation
In February 2015, we reported that we were the target of a sophisticated external cyber attack during which the attackers gained unauthorized access to certain
of our information technology systems and obtained personal information related to many individuals and employees. To date, there is no evidence that credit card
or medical information was accessed or obtained. Upon discovery of the cyber attack, we took immediate action to remediate the security vulnerability and have
continued to implement security enhancements since this incident.
Federal and state agencies are investigating, or have investigated, events related to the cyber attack, including how it occurred, its consequences and our
responses. The investigations have all been resolved with the exception of an ongoing investigation by a multi-state group of attorneys general, which remains
outstanding. Although we are cooperating in this investigation, we may be subject to additional fines or other obligations. We intend to vigorously defend the
remaining regulatory investigation; however, its ultimate outcome cannot be presently determined.
We have contingency plans and insurance coverage for certain expenses and potential liabilities of this nature and will pursue coverage for all applicable
losses; however, the ultimate outcome of our pursuit of insurance coverage cannot be presently determined.
-28-

-- 32 of 97 --

Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the
ordinary course of business. We, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO and
other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for
uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the
risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are
from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews
and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines,
penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these
actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through
June 2025. The new agreement supersedes certain prior agreements for services and includes provisions for additional services not provided under those
agreements. Our aggregate commitment under this agreement is approximately 	$1,700. We will have the ability to terminate the agreement upon the occurrence of
certain events, subject to early termination fees.
In the second quarter of 2019, we began using our new pharmacy benefits manager named IngenioRx, Inc., or IngenioRx, to market and offer PBM services to
fully-insured and self-funded Anthem health plan customers throughout the country, as well as to external customers outside of the health plans we own. The
comprehensive prescription benefits management services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug
database, member services and mail order capabilities. Also in the second quarter of 2019, IngenioRx began delegating certain PBM administrative functions, such
as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C.,which is a subsidiary of CVS Health Corporation, pursuant to a five-year
agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations,
sales, marketing, account management and retail network strategy. From December 2009 through December 2019, we delegated certain PBM functions and
administrative services to Express Scripts pursuant to the ESI PBM Agreement. In January 2019, we exercised our contractual right to terminate the ESI PBM
Agreement earlier than the original expiration date of December 31, 2019, due to the acquisition of Express Scripts by Cigna. We began transitioning existing
members from Express Scripts to IngenioRx in the second quarter of 2019, and completed the transition of all of our members by January 1, 2020. Prior to the
termination of the ESI PBM Agreement, Express Scripts managed the network of pharmacy providers, operated mail order pharmacies and processed prescription
drug claims on our behalf, while we sold and supported the product for our members, made formulary decisions, sold drug benefit design strategy and provided
front line member support. Express Scripts continues to provide certain audit and run out transition services related to our PBM business. Notwithstanding our
termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information
regarding this lawsuit, refer to the 	Litigation and Regulatory Proceedings–Express Scripts, Inc. Pharmacy Benefit Management Litigation 	section above. We
believe we have appropriately recognized all rights and obligations under the ESI PBM Agreement as of March 31, 2020.
12. 	Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is
-29-

-- 33 of 97 --

at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital
requirements and other factors deemed relevant by our Board of Directors.
A summary of the cash dividend activity for the 	three months ended March 31, 2020 	and 	2019 	is as follows:
Declaration Date 	Record Date 	Payment Date
Cash
Dividend
per Share 	Total
Three Months Ended March 31, 2020
January 28, 2020 	March 16, 2020 	March 27, 2020 	$0.95 	$ 	240
Three Months Ended March 31, 2019
January 29, 2019 	March 18, 2019 	March 29, 2019 	$0.80 	$ 	206
On April 28, 2020, our Audit Committee declared a second quarter 2020 dividend to shareholders of 	$0.95 	per share, payable on 	June 25, 2020 	to shareholders
of record at the close of business on 	June 10, 2020.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On December 7, 2017, the Board of Directors authorized a
$5,000 	increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions
on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share
repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase
program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of
capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. We have
temporarily suspended our share repurchase program given the market volatility.
A summary of common stock repurchases for the 	three months ended March 31, 2020 	and 	2019 	is as follows:
Three Months Ended March 31
2020 	2019
Shares repurchased 	1.9 	1.1
Average price per share 	$ 	275.38 	$ 	275.23
Aggregate cost 	$ 	529 	$ 	294
Authorization remaining at the end of the period 	$ 	3,263 	$ 	5,199
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt” of this Form 10-Q and Note 12, “Debt,” to our
audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our 	2019 	Annual Report on Form 10-K.
-30-

-- 34 of 97 --

Stock Incentive Plans
A summary of stock option activity for the 	three months ended March 31, 2020 	is as follows:
Number of
Shares
Weighted-
Average
Option Price
per Share
Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2020 	3.1 	$ 	190.31
Granted 	1.0 	271.27
Exercised 	(0.3) 	107.46
Forfeited or expired 	— 	256.05
Outstanding at March 31, 2020 	3.8 	216.40 	7.15 	$ 	139
Exercisable at March 31, 2020 	2.2 	171.44 	5.57 	$ 	139
A summary of the nonvested restricted stock activity, including restricted stock units, for the 	three months ended March 31, 2020 	is as follows:
Restricted
Stock Shares
and Units
Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2020 	1.4 	$ 	242.47
Granted 	1.2 	272.03
Vested 	(1.1) 	193.23
Forfeited 	(0.1) 	264.40
Nonvested at March 31, 2020 	1.4 	271.00
During the 	three months ended March 31, 2020, we granted approximately 	0.2 	restricted stock units that are contingent upon us achieving earnings targets
over the three year period from 2020 to 2022. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2022
based on results in the three year period.
During the three months ended March 31, 2020, we granted an additional 	0.6 	restricted stock units associated with our 2017 grants that were earned as a result
of satisfactory completion of performance measures between 2017 and 2019. These grants and vested shares have been included in the activity shown above.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair
value methodology, see Note 14, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our
2019 	Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the 	three months ended March 31, 2020 	and
2019:
Three Months Ended March 31
2020 	2019
Risk-free interest rate 	1.30% 	2.69%
Volatility factor 	26.00% 	25.00%
Quarterly dividend yield 	0.350% 	0.260%
Weighted-average expected life (years) 	4.30 	4.40
-31-

-- 35 of 97 --

The following weighted-average fair values per option or share were determined for the 	three months ended March 31, 2020 	and 	2019:
Three Months Ended March 31
2020 	2019
Options granted during the period 	$ 	54.03 	$ 	68.92
Restricted stock awards granted during the period 	272.03 	307.59
13. 	Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at 	March 31, 2020 	and 	2019 	is as follows:
March 31
2020 	2019
Investments:
Gross unrealized gains 	$ 	510 	$ 	379
Gross unrealized losses 	(729) 	(121)
Net pre-tax unrealized (losses) gains 	(219) 	258
Deferred tax asset (liability) 	51 	(61)
Net unrealized (losses) gains on investments 	(168) 	197
Non-credit components of impairments on investments:
Unrealized losses 	(44) 	(3)
Deferred tax asset 	10 	1
Net unrealized non-credit component of impairments on investments 	(34) 	(2)
Cash flow hedges:
Gross unrealized losses 	(327) 	(308)
Deferred tax asset 	68 	65
Net unrealized losses on cash flow hedges 	(259) 	(243)
Defined benefit pension plans:
Deferred net actuarial loss 	(724) 	(744)
Deferred prior service credits 	— 	(1)
Deferred tax asset 	185 	191
Net unrecognized periodic benefit costs for defined benefit pension plans 	(539) 	(554)
Postretirement benefit plans:
Deferred net actuarial loss 	(25) 	(57)
Deferred prior service costs 	18 	31
Deferred tax asset 	2 	7
Net unrecognized periodic benefit costs for postretirement benefit plans 	(5) 	(19)
Foreign currency translation adjustments:
Gross unrealized losses 	(4) 	(3)
Deferred tax asset 	1 	1
Net unrealized losses on foreign currency translation adjustments 	(3) 	(2)
Accumulated other comprehensive loss 	$ 	(1,008) 	$ 	(623)
-32-

-- 36 of 97 --

Other comprehensive income (loss) reclassification adjustments for the 	three 	months ended 	March 31, 2020 	and 	2019 	are as follows:
Three Months Ended March 31
2020 	2019
Investments:
Net holding (loss) gain on investment securities arising during the period, net of tax benefit (expense) of $213 and
$(98), respectively 	$ 	(716) 	$ 	350
Reclassification adjustment for net realized gains on investment securities, net of tax benefit of $7 and $2,
respectively 	27 	7
Total reclassification adjustment on investments 	(689) 	357
Non-credit component of impairments on investments:
Non-credit component of impairments on investments, net of tax benefit of $9 	(32) 	—
Cash flow hedges:
Holding gain, net of tax expense of ($1) and ($0), respectively 	3 	3
Other:
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net
of tax expense of ($3) and ($1), respectively 	7 	3
Foreign currency translation adjustment, net of tax expense of ($0) and ($0), respectively 	(1) 	—
Net (loss) gain recognized in other comprehensive income, net of tax benefit (expense) of $211 and $(101), respectively 	$ 	(712) 	$ 	363
14. 	Earnings per Share
The denominator for basic and diluted earnings per share for the 	three 	months ended 	March 31, 2020 	and 	2019 	is as follows:
Three Months Ended
March 31
2020 	2019
Denominator for basic earnings per share – weighted-average shares 	252.4 	257.1
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures 	4.0 	5.2
Denominator for diluted earnings per share 	256.4 	262.3
During the 	three 	months ended 	March 31, 2020 	and 	2019, weighted-average shares related to certain stock options of 	0.9 	and 	0.2, respectively, were excluded
from the denominator for diluted earnings per share because the stock options were anti-dilutive.
During the 	three months ended March 31, 2020, we issued approximately 	1.2 	restricted stock units under our stock incentive plans, 	0.2 	of which vesting is
contingent upon us meeting specified annual earnings targets for the three year period of 	2020 	through 2022. During the 	three months ended 	March 31, 2019, we
issued approximately 	0.5 	restricted stock units under our stock incentive plans, 	0.2 	of which vesting is contingent upon us meeting specified annual earnings targets
for the three year period of 2019 through 2021. The contingent restricted stock units have been excluded from the denominator for diluted earnings per share and
will be included only if and when the contingency is met.
-33-

-- 37 of 97 --

15. 	Segment Information
Beginning in 2020, IngenioRx meets the quantitative thresholds for a reportable segment based on the FASB guidance. The results of our operations are now
described through 	four 	reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other.
Our Commercial & Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the
Commercial & Specialty Business segment offer fully-insured health products; provide a broad array of managed care services to self-funded customers including
claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness
programs and other administrative services; and provide an array of specialty and other insurance products and services such as dental, vision, life and disability
insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, or NGS, and services provided to the
federal government in connection with the FEHB program. Our Medicare business includes services such as Medicare Supplement plans; Medicare Advantage,
including Special Needs Plans; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans. Our Medicaid business includes our managed care
alternatives through publicly funded healthcare programs, including Medicaid, Medicaid expansion programs related to the Patient Protection and Affordable Care
Act and the Health Care and Education Reconciliation Act of 2010, amended, Temporary Assistance for Needy Families, programs for seniors and people with
disabilities, Children’s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care,
behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities. NGS acts as a Medicare contractor for the federal
government in several regions across the nation.
Our IngenioRx segment includes our PBM business, which began its operations during the second quarter of 2019. IngenioRx markets and offers PBM
services to fully-insured and self-funded Anthem health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a
comprehensive prescription benefits management services portfolio which includes services, such as formulary management, pharmacy networks, prescription
drug database, member services and mail order capabilities.
Our Other segment includes our Diversified Business Group, or DBG, which is our integrated health services business, certain eliminations and corporate
expenses not allocated to our other reportable segments. We reclassified DBG from our Government Business segment to the Other segment during the second
quarter of 2019 to reflect changes in how our segments are being managed. Amounts for the three months ended March 31, 2019 have been reclassified to conform
to the current year presentation for comparability. Also, beginning on February 28, 2020, DBG includes Beacon.
For our 2019 segment reporting, operating gains (losses) generated from IngenioRx and DBG affiliated activity were included in our Commercial & Specialty
Business and Government Business segments based upon their utilization of services from IngenioRx and DBG, which aligns with the method by which we
assessed the 2019 operating performance of our reportable segments. 	Beginning January 1, 2020, we are managing the operating performance of each of our
segments on a standalone basis.
Affiliated revenues represent revenues or cost for services provided by IngenioRx and DBG to our subsidiaries, are recorded at cost or management’s estimate
of fair market value, and are eliminated in consolidation.
-34-

-- 38 of 97 --

Financial data by reportable segment for the 	three 	months ended 	March 31, 2020 	and 	2019 	is as follows:
Commercial
& Specialty
Business
Government
Business 	IngenioRx 	Other 	Eliminations 	Total
Three Months Ended March 31, 2020
Operating revenue - unaffiliated 	$ 	9,361 	$ 	17,466 	$ 	2,344 	$ 	277 	$ 	— 	$ 	29,448
Operating revenue - affiliated 	— 	— 	2,853 	750 	(3,603) 	—
Operating gain 	1,420 	411 	349 	14 	— 	2,194
Three Months Ended March 31, 2019
Operating revenue - unaffiliated 	$ 	9,392 	$ 	14,925 	$ 	— 	$ 	71 	$ 	— 	$ 	24,388
Operating revenue - affiliated 	— 	— 	— 	477 	(477) 	—
Operating gain (loss) 	1,598 	374 	— 	(32) 	— 	1,940
The major product revenues for each of the reportable segments for the 	three 	months ended 	March 31, 2020 	and 	2019 	are as follows:
Three Months Ended
March 31
2020 	2019
Commercial & Specialty Business
Managed care products 	$ 	7,569 	$ 	7,618
Managed care services 	1,381 	1,366
Dental/Vision products and services 	315 	323
Other 	96 	85
Total Commercial & Specialty Business 	9,361 	9,392
Government Business
Managed care products 	17,375 	14,821
Managed care services 	91 	104
Total Government Business 	17,466 	14,925
IngenioRx
Pharmacy products and services 	5,197 	—
Total IngenioRx 	5,197 	—
Other
Other 	1,027 	548
Eliminations
Eliminations 	(3,603) 	(477)
Total product revenues 	$ 	29,448 	$ 	24,388
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed.
Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we
provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.
-35-

-- 39 of 97 --

A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the 	three
months ended 	March 31, 2020 	and 	2019 	is as follows:
Three Months Ended
March 31
2020 	2019
Reportable segments’ operating revenue 	$ 	29,448 	$ 	24,388
Net investment income 	254 	210
Net realized (losses) gains on financial instruments 	(24) 	78
Impairment losses recognized in income 	(57) 	(10)
Total revenues 	$ 	29,621 	$ 	24,666
A reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the 	three
months ended 	March 31, 2020 	and 	2019 	is as follows:
Three Months Ended
March 31
2020 	2019
Reportable segments’ operating gain 	$ 	2,194 	$ 	1,940
Net investment income 	254 	210
Net realized (losses) gains on financial instruments 	(24) 	78
Impairment losses recognized in income 	(57) 	(10)
Interest expense 	(194) 	(187)
Amortization of other intangible assets 	(83) 	(87)
(Loss) gain on extinguishment of debt 	(1) 	1
Income before income tax expense 	$ 	2,089 	$ 	1,945
-36-

-- 40 of 97 --

16. 	Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 	1 	year to 	15
years.
The information related to our leases is as follows:
Balance Sheet Location 	March 31, 2020 	December 31, 2019
Operating Leases
Right-of-use assets 	Other noncurrent assets 	$ 	915 	$ 	575
Lease liabilities, current 	Other current liabilities 	195 	158
Lease liabilities, noncurrent 	Other noncurrent liabilities 	801 	482
Three Months Ended March
31, 2020
Three Months Ended March
31, 2019
Lease Expense
Operating lease expense 	$ 	47 	$ 	45
Short-term lease expense 	13 	12
Sublease income 	(3) 	(4)
Total lease expense 	$ 	57 	$ 	53
Other information
Operating cash paid for amounts included in the measurement of lease liabilities, operating leases 	$ 	44 	$ 	44
Right-of-use assets obtained in exchange for new lease liabilities, operating leases 	$ 	323 	$ 	—
Weighted average remaining lease term, operating leases 	7.2 years 	6.5 years
Weighted average discount rate, operating leases 	3.57% 	3.97%
At 	March 31, 2020, future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2020 (excluding the three months ended March 31, 2020) 	$ 	140
2021 	178
2022 	161
2023 	140
2024 	110
Thereafter 	288
Total future minimum payments 	1,017
Less imputed interest 	(21)
Total lease liabilities 	$ 	996
As of 	March 31, 2020, we have additional operating leases for building spaces that have not yet commenced, and some building spaces are being constructed
by the lessors and their agents. These leases have terms of up to 	12 	years and 	are expected to commence on various dates during 2020 and 2021 when the
construction is complete and we take possession of the buildings. The undiscounted lease payments for these leases, which are not included in the tables above,
aggregate 	$226.
-37-

-- 41 of 97 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with the
accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, 2019 and the
MD&A included in our 2019 Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” or “Anthem” used throughout this MD&A refer to Anthem,
Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of
Columbia, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the 	three 	months ended 	March 31, 2020 	are not necessarily indicative of
the results and trends that may be expected for the full year ending 	December 31, 2020, or any other period.
Overview
We are one of the largest health benefits companies in the United States in terms of medical membership, serving approximately 	42 	million 	medical members
through our affiliated health plans as of 	March 31, 2020. 	We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or
BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 	30 	counties in the Kansas City area), Nevada, New
Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington,
D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross
Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our
subsidiaries, we also serve customers in numerous 	states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon Health, CareMore,
Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing
prescription benefits management, or PBM, services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the
District of Columbia through our subsidiaries.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7 “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” included in our 2019 Annual Report on Form 10-K. Additional information on our segments can be found in this MD&A
and in Note 15, “Segment Information” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
COVID-19
In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, or COVID-19, a global health pandemic and
recommended containment and mitigation measures worldwide. Since then, the COVID-19 outbreak has also been declared a national health emergency in the
United States and continues to spread domestically and in other countries globally. To prevent the spread of this virus, most states have issued shelter-in-place or
stay-at-home orders, which generally require businesses not considered essential to close their physical offices. The virus and efforts to prevent its spread have also
drastically impacted the global economy, causing market instability and increasing unemployment in the United States.
In response to the COVID-19 pandemic, federal and state legislation has been, and we expect will continue to be, enacted that will impact our business. For
additional information on existing legislation related to the impact of the COVID-19 pandemic on our business, see “Regulatory Trends and Uncertainties” in this
MD&A.
To better serve our members, we have introduced new resources and taken proactive steps that can help provide increased access to care for our members. We
have launched an online COVID-19 symptom assessment tool and enhanced the digital capabilities of Sydney Care, our mobile app, to include a symptom checker
feature, as well as virtual text visit and video visit features. The symptom checker feature guides users through the resulting action plan depending upon the results
of the user’s assessment, and the virtual text feature connects users to certified physicians who can provide medical care
-38-

-- 42 of 97 --

including prescribing medication and ordering lab work during consults as necessary. We are providing virtual visits through our LiveHealth Online service,
including visits for mental health, and waiving cost share until June 14, 2020 for telehealth visits for our members in fully-insured employer plans, Individual
plans, Medicare plans and Medicaid plans, where permissible. Further, we have relaxed early prescription refill policies for maintenance and specialty medications
and are encouraging the use of home delivery services to ensure access to necessary medications.
We have also made other changes to our membership benefits and business operations and may make additional changes in the future. We suspended select
prior authorization requirements to allow care providers to focus on caring for our members diagnosed with COVID-19. While not mandated, on April 1, 2020, to
meet the needs of those directly impacted by the COVID-19 disease, we expanded coverage for certain members in our affiliated health plans undergoing treatment
related to a COVID-19 diagnosis. The expansion waives cost sharing for COVID-19 treatment received through May 31, 2020, and we will reimburse health care
providers at in-network rates or Medicare rates, as applicable, for our affiliated health plan fully insured employer, Individual, Medicaid and Medicare Advantage
members. In addition, government action required us to provide full coverage for COVID-19 testing to our members, and future governmental action could require
us to provide additional coverage related to COVID-19 treatments. We are in frequent communication with our employer groups in an effort to support them in
these unprecedented times and we serve as a resource for employers looking for health coverage options.
The safety, health and wellbeing of our employees remains a top priority as we face these challenges together, and continue our work in support of those we
serve. To protect our employees and mitigate the spread of COVID-19, we have imposed travel limitations and directed our employees to work remotely whenever
possible, with nearly all of our employees working remote. We have expanded our employee benefits to provide additional support, including up to 80 hours of
paid emergency leave if employees are experiencing symptoms of COVID-19 or carrying for young children whose schools have been closed. We are also
expanding the use of sick time to include caregiving related to COVID-19. Furthermore, we have taken additional precautions with regard to workspace
modifications and sanitation of our facilities.
The COVID-19 pandemic, including the changes we made in response to and any further steps taken to expand or otherwise modify the services delivered to
our members, could have a material adverse impact on our business, cash flows, financial condition and results of operations. These impacts include, but are not
limited to, the following:
◦ 	Our covered medical expenses may rise;
◦ 	Our membership may decline;
◦ 	Our membership mix may change to less profitable lines of business;
◦ 	Premium receipts from our Commercial and Government customers may be delayed or uncollectable;
◦ 	Reimbursements for benefit payments made on behalf of our self-insured customers may be delayed or uncollectable;
◦ 	Our suppliers’ operations may be interrupted;
◦ 	Our operations may be interrupted;
◦ 	Our access to credit to meet liquidity may become limited and our credit rating may be negatively impacted; and
◦ 	Our investment returns may be reduced and investment values may become impaired.
We are focused on navigating these challenges and have taken certain measures to address the impacts of the COVID-19 pandemic. In particular, we are
taking several actions to preserve our liquidity and financial flexibility. Such measures include, but are not limited to, borrowing under our senior revolving credit
facility, delaying certain tax payments as permitted by the Internal Revenue Service and the Coronavirus Aid, Relief, and Economic Security, or CARES, Act,
increasing our borrowings from existing or new Federal Home Loan Bank memberships, reducing our discretionary spending and temporarily suspending our share
repurchase activity.
We continue to closely monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes that may impact our business. For additional
discussion regarding our risk factors, see Part I, Item 1A, “Risk Factors” included in our 2019 Annual Report on Form 10-K and Part II, Item 1A, “Risk Factors” of
this Form 10-Q.
Business Trends
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, has
changed and may continue to make broad-based changes to the U.S. healthcare system. We expect the ACA will continue to impact our business model and
strategy. Also, the legal challenges regarding the
-39-

-- 43 of 97 --

ACA, including a federal district court decision invalidating the ACA, or the 2018 ACA Decision, which judgment has been stayed pending appeal, could
significantly disrupt our business. During 2019, we modestly expanded our participation in the Individual ACA-compliant market. Our strategy has been, and will
continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability,
including, but not limited to, factors such as expected financial performance, regulatory environment, and underlying market characteristics. We currently offer
Individual ACA-compliant products in 91 of the 143 rating regions in which we operate. In addition, the continuing growth in our government-sponsored business
exposes us to increased regulatory oversight.
In the second quarter of 2019, we began using IngenioRx to market and offer PBM services to fully-insured and self-funded Anthem health plan customers
throughout the country, as well as to external customers outside of the health plans we own. The comprehensive PBM services portfolio includes services such as
formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. In July 2019, we announced our first
contract win with a third-party health insurer, Blue Cross of Idaho, and IngenioRx began providing PBM services under that contract on January 1, 2020. Also in
the second quarter of 2019, IngenioRx began delegating certain PBM administrative functions, such as claims processing and prescription fulfillment, to
CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities
for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network
strategy. From December 2009 through December 2019, we delegated certain PBM functions and administrative services to Express Scripts Inc., or Express
Scripts, pursuant to our PBM agreement with Express Scripts, or the ESI PBM Agreement. We began transitioning existing members from Express Scripts to
IngenioRx in the second quarter of 2019, and completed the transition of all of our members by January 1, 2020. We expect IngenioRx to provide our members
with more cost-effective solutions and improve our ability to integrate pharmacy benefits within our medical and specialty platform.
Pricing Trends: 	We strive to price our healthcare benefit products consistent with anticipated underlying medical cost trends. We frequently make adjustments to
respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our
Commercial & Specialty Business segment, including our Individual and Small Group lines of business, remains competitive. Revenues from the Medicare and
Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. The ACA imposed
an annual Health Insurance Provider Fee, or HIP Fee, on health insurers that write certain types of health insurance on U.S. risks. We price our affected products to
cover the impact of the HIP Fee, when applicable. The HIP Fee was suspended for 2019, has resumed for 2020 and has been permanently eliminated beginning in
2021.
Medical Cost Trends: 	Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of
these services. We work to mitigate these trends through various medical management programs such as utilization management, condition management, program
integrity and specialty pharmacy management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our
estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics
of our members, epidemics, pandemics, advances in medical technology, new high cost prescription drugs, and healthcare provider or member fraud. Our
underlying Local Group medical cost trends reflect the “allowed amount,” or contractual rate, paid to providers. The COVID-19 pandemic has caused, and may
continue to cause, deferral of non-emergent or elective health services, which could decrease our claim costs in the short-term and increase our claim costs in the
long-term and affect our medical cost trends. Further, the amount and frequency of covered services related to the COVID-19 disease could have a material adverse
effect on our claim costs. In response to the current crisis, we expanded coverage for certain members in our affiliated health plans undergoing treatment related to
a COVID-19 diagnosis. The expansion waives cost sharing for COVID-19 treatment received through May 31, 2020. Governmental action has required us to
provide full coverage for COVID-19 testing to our members, and future governmental action could require us to provide additional coverage. We continue to
closely monitor the COVID-19 pandemic and its impacts to our business, financial condition, results of operations and medical cost trend.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2019 Annual Report on Form 10-K.
-40-

-- 44 of 97 --

Regulatory Trends and Uncertainties
Federal and state legislation has been enacted, and is likely to continue to be enacted, in response to the COVID-19 pandemic that have had, and we expect
will continue to have, a significant impact on all of our lines of business, including mandates to waive cost-sharing on COVID-19 testing and related services. As
of April 21, 2020, the federal government has enacted the following four pieces of legislation addressing the COVID-19 pandemic, among others:
◦ 	Signed into law on March 6, 2020, the Coronavirus Preparedness and Response Supplemental Appropriations Act provided supplemental appropriations
for the Department of Health and Human Services, the State Department, and the Small Business Administration to respond to the COVID-19 pandemic,
as well as certain reforms, including waiving Medicare originating site restrictions for qualified providers providing telehealth services.
◦ 	Signed into law on March 19, 2020, the Families and Workers First Act enacted a prohibition on prior authorization and cost-sharing for certain items and
services related to COVID-19 tests.
◦ 	Signed into law on March 27, 2020, the CARES Act provided financial support to health care providers, including expansion of the Medicare accelerated
payment program to all providers receiving Medicare payments. The CARES Act also provided a broad lending program for small businesses to help
keep their workers employed and healthcare benefits covered in the group market.
◦ 	Signed into law on April 24, 2020, the Paycheck Protection Program and Health Care Enhancement Act allocated additional funds to replenish and
administer small business loan programs and increased financial support to providers and bolstered COVID-19 testing.
In addition, these legislative reforms and the Internal Revenue Service Notice 2020-23, or IRS Notice 2020-23, issued in 	April 2020 in response to the
COVID-19 pandemic included tax deferrals and other beneficial provisions, including delay of certain payroll and federal income tax payments, which we expect
to have a positive impact on our 2020 cash flows. For more information on measures we have taken to increase our cash on hand, see “Future Sources and Uses of
Liquidity” in this MD&A.
Regulatory changes have also been enacted, and are likely to continue to be enacted, at the state and federal level in response to the COVID-19 pandemic.
Those changes, which could have a significant impact on health benefits, consumer eligibility for public programs, and cash flows, include mandated expansion of
premium payment terms including the time period for which claims can be denied for lack of payment, mandates related to prior authorizations and payment levels
to providers, additional consumer enrollment windows, and increased ability to provide services through telehealth. We have begun providing extensions to
premium payment terms in certain situations and continue to work closely with state regulators that are mandating or requesting such relief.
The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required changes in the way
products are designed, underwritten, priced, distributed and administered. Changes to our business environment are likely to continue as elected officials at the
national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and
regulations, including changes to taxes and fees. In addition, the legal challenges regarding the ACA, including the 2018 ACA Decision, which judgment has been
stayed pending appeal, continue to contribute to this uncertainty. In a separate development, in April 2020, the U.S. Supreme Court ruled that the federal
government is required to pay health insurance companies for amounts owed, as calculated under the risk corridor program of the ACA. We will review this ruling
and recognize the impact, if any, in a future reporting period. We will continue to evaluate the impact of the ACA as any further developments or judicial rulings
occur.
The annual HIP Fee is allocated to health insurers based on the ratio of the amount of an insurer’s net premium revenues written during the preceding calendar
year to the amount of health insurance premium for all U.S. health risk for those certain lines of business written during the preceding calendar year. We record our
estimated liability for the HIP Fee in full at the beginning of the year with a corresponding deferred asset that is amortized on a straight-line basis to selling,
general and administrative expense. The final calculation and payment of the annual HIP Fee is due by September 30th 	of each fee year. The HIP Fee is non-
deductible for federal income tax purposes. Our affected products are priced to cover the increased selling, general and administrative and income tax expenses
associated with the HIP Fee. The total amount due from allocations to all health insurers is 	$15,523 	for 2020. For the 	three 	months ended March 31, 2020, we
estimated our portion
-41-

-- 45 of 97 --

of the HIP Fee to be 	$417, which was recognized as general and administrative expense. There was no corresponding expense for 2019 due to the suspension of the
HIP Fee for 2019.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business - Regulation” and Part I, Item 1A, “Risk
Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” included in our 2019 Annual Report on Form 10-K and Part II, Item 1A, “Risk Factors” of this Form 10-Q.
Other Significant Items
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligns with our strategy to
diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions.
For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q.
In January 2019, we exercised our contractual right to terminate the ESI PBM Agreement, and we completed the transition of our members from Express
Scripts to IngenioRx on January 1, 2020. Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the
ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 11, “Commitments and Contingencies - 	Litigation and Regulatory
Proceedings - Express Scripts, Inc. Pharmacy Benefit Management Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this
Form 10-Q.
In May 2017, we announced that we were terminating the Agreement and Plan of Merger, or Cigna Merger Agreement, between us and Cigna Corporation.
For additional information about ongoing litigation related to the Cigna Merger Agreement, see Note 11, “Commitments and Contingencies - 	Litigation and
Regulatory Proceedings - Cigna Corporation Merger Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Selected Operating Performance
For the twelve months ended 	March 31, 2020, total medical membership 	increased 	1.3, or 	3.2%. Our medical membership grew in both Government Business
and Commercial & Specialty Business segments. The increase in medical membership in our Government Business segment was primarily due to fully-insured
membership growth in our Medicaid and Medicare businesses. The increase in medical membership in our Commercial & Specialty Business segment was
primarily driven by growth in our self-funded business, partially offset by declines in our fully-insured membership.
Operating revenue for the 	three months ended March 31, 2020 	was 	$29,448, 	an increase 	of 	$5,060, or 	20.7%, from the 	three months ended March 31, 2019.
The increase was driven by pharmacy product revenue related to the launch of IngenioRx. The increase was further attributable to higher premium revenue from
rate increases across our businesses designed to cover overall cost trends and the impact of the HIP Fee reinstatement for 2020, and membership growth in our
Government Business segment.
Net income for the 	three months ended March 31, 2020 	was 	$1,523, 	a decrease 	of 	$28, or 	1.8%, from the 	three months ended March 31, 2019. The decrease in
net income was primarily due to lower operating results in our Commercial & Specialty Business segment, higher income tax expense due to the HIP Fee
reinstatement for 2020 and net realized losses on financial instruments compared to net realized gains on financial instruments in the three months ended March 31,
2019. The decrease in net income was partially offset by favorable operating results in our IngenioRx segment and higher operating results in our Other and
Government Business segments.
Our diluted earnings per share, or EPS, was 	$5.94 	for the 	three months ended March 31, 2020, which represented a 	0.5% 	increase 	from EPS of 	$5.91 	for the
three months ended March 31, 2019. This 	increase 	resulted from the impact of a lower number of shares outstanding in 2020, partially offset by the decrease in net
income.
-42-

-- 46 of 97 --

Operating cash flow for the 	three months ended March 31, 2020 	and 	2019 	was 	$2,515 	and 	$1,630, respectively. This 	increase 	was 	primarily attributable to
higher premium receipts as a result of the HIP Fee reinstatement in 2020 as well as other changes in working capital.
Membership
The following table presents our medical membership by customer type, funding arrangement and reportable segment as of 	March 31, 2020 	and 	2019. Also
included below is other membership by product. At this time, the following table does not include membership resulting from our acquisition of Beacon. The
medical membership and other membership data presented are unaudited and in certain instances include estimates of the number of members represented by each
contract at the end of the period. 	For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” included in our 	2019 	Annual Report on Form 10-K.
March 31
(In thousands) 	2020 	2019 	Change 	% Change
Medical Membership
Customer Type
Local Group 	15,848 	15,697 	151 	1.0 	%
Individual 	717 	773 	(56) 	(7.2)%
National:
National Accounts 	7,898 	7,757 	141 	1.8 	%
BlueCard® 	6,197 	5,981 	216 	3.6 	%
Total National 	14,095 	13,738 	357 	2.6 	%
Medicare:
Medicare Advantage 	1,341 	1,144 	197 	17.2 	%
Medicare Supplement 	914 	867 	47 	5.4 	%
Total Medicare 	2,255 	2,011 	244 	12.1 	%
Medicaid 	7,615 	7,033 	582 	8.3 	%
Federal Employees Health Benefits 	1,614 	1,591 	23 	1.4 	%
Total Medical Membership by Customer Type 	42,144 	40,843 	1,301 	3.2 	%
Funding Arrangement
Self-Funded 	26,120 	25,495 	625 	2.5 	%
Fully-Insured 	16,024 	15,348 	676 	4.4 	%
Total Medical Membership by Funding Arrangement 	42,144 	40,843 	1,301 	3.2 	%
Reportable Segment
Commercial & Specialty Business 	30,660 	30,208 	452 	1.5 	%
Government Business 	11,484 	10,635 	849 	8.0 	%
Total Medical Membership by Reportable Segment 	42,144 	40,843 	1,301 	3.2 	%
Other Membership
Life and Disability Members 	5,158 	4,849 	309 	6.4 	%
Dental Members 	6,172 	5,955 	217 	3.6 	%
Dental Administration Members 	1,311 	5,491 	(4,180) 	(76.1)%
Vision Members 	7,510 	7,169 	341 	4.8 	%
Medicare Part D Standalone Members 	383 	289 	94 	32.5 	%
-43-

-- 47 of 97 --

Medical Membership
Total medical membership grew in both Government Business and Commercial & Specialty Business segments as well as by funding arrangement. Fully-
insured membership increased primarily due to growth in our Medicaid and Medicare businesses, partially offset by the membership decreases in our fully-insured
Local Group business resulting from lapses and in-group change exceeding sales and in our Individual business resulting from attrition in our non-ACA-compliant
off-exchange product offerings. Self-funded medical membership increased primarily as a result of higher BlueCard® 	activity at other Blue Cross Blue Shield
Association, or BCBSA, plans whose members reside in or travel to our licensed areas. The increase in self-funded membership was further attributable to
membership increases in our National Accounts business resulting from our acquisition of a third-party administrator, or TPA, and in our Local Group self-funded
business resulting from in-group change. Medicaid membership 	increased 	primarily due to our acquisition of Medicaid plans in Missouri and Nebraska and organic
growth in existing markets. Medicare membership 	increased 	primarily due to higher sales during open enrollment exceeding lapses. Local Group membership
increased due to our TPA acquisition, new sales and favorable in-group change exceeding lapses. National Accounts membership increased primarily due to our
TPA acquisition.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to
our health business. We have experienced growth in our life and disability and dental memberships primarily due to higher sales in our Local Group business.
Dental administration membership decreased due to the lapse of a large dental administration services contract. Vision membership increased due to higher sales in
our Medicare and Local Group businesses.
-44-

-- 48 of 97 --

Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the 	three 	months ended 	March 31, 2020 	and 	2019 	are as follows:
Three Months Ended
March 31
2020 	2019 	$ Change 	% Change
Total operating revenue 	$ 	29,448 	$ 	24,388 	$ 	5,060 	20.7 	%
Net investment income 	254 	210 	44 	21.0 	%
Net realized (losses) gains on financial instruments 	(24) 	78 	(102) 	(130.8)%
Impairment losses recognized in income 	(57) 	(10) 	(47) 	470.0 	%
Total revenues 	29,621 	24,666 	4,955 	20.1 	%
Benefit expense 	21,489 	19,282 	2,207 	11.4 	%
Cost of products sold 	1,984 	— 	1,984 	NM
Selling, general and administrative expense 	3,781 	3,166 	615 	19.4 	%
Other expense1 	278 	273 	5 	1.8 	%
Total expenses 	27,532 	22,721 	4,811 	21.2 	%
Income before income tax expense 	2,089 	1,945 	144 	7.4 	%
Income tax expense 	566 	394 	172 	43.7 	%
Net income 	$ 	1,523 	$ 	1,551 	$ 	(28) 	(1.8)%
Average diluted shares outstanding 	256.4 	262.3 	(5.9) 	(2.2)%
Diluted net income per share 	$ 	5.94 	$ 	5.91 	$ 	0.03 	0.5 	%
Effective tax rate 	27.1% 	20.3% 	680bp3
Benefit expense ratio2 	84.2% 	84.4% 	(20)bp3
Selling, general and administrative expense ratio4 	12.8% 	13.0% 	(20)bp3
Income before income tax expense as a percentage of total revenues 	7.1% 	7.9% 	(80)bp3
Net income as a percentage of total revenues 	5.1% 	6.3% 	(120)bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM 	Not meaningful.
1 	Includes interest expense, amortization of other intangible assets and (gain) loss on extinguishment of debt.
2 	Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the 	three months ended March 31, 2020 	and 	2019 	were 	$25,517 	and 	$22,843,
respectively. Premiums are included in total operating revenue presented above.
3 	bp = basis point; one hundred basis points = 1%.
4 	Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.
Three Months Ended March 31, 2020 	Compared to the 	Three Months Ended March 31, 2019
The increase in total operating revenue was primarily due to product revenue and higher premiums. Product revenue represents services performed by our
IngenioRx pharmacy benefit manager for unaffiliated PBM customers as well as ingredient costs (net of any rebates or discounts), including co-payments made by
or on behalf of the customer, and administrative fees. There was no product revenue recognized in the three months ended March 31, 2019, as IngenioRx began its
operations during the second quarter of 2019. The higher premiums were due to rate increases across our businesses designed to cover overall cost trends and the
impact of the HIP Fee reinstatement for 2020, and membership growth in our Government Business segment.
-45-

-- 49 of 97 --

We recognized net realized losses on financial instruments in the first quarter of 2020 compared to net realized gains on financial instruments in the first
quarter of 2019. This change was primarily due to a decrease in net realized gains on equity securities reflecting the changes in their fair values during the three
months ended March 31, 2020.
Benefit expense 	increased 	primarily due to increased costs as a result of growth in our Medicare and Medicaid membership and overall cost trends across our
businesses.
Our benefit expense ratio 	decreased 	largely due to the impact of the HIP Fee reinstatement for 2020. This decrease was partially offset by the leap year impact
of an extra day of claims in the three months ended March 31, 2020 as associated premiums are recognized ratably throughout the year, and margin normalization
in our Individual business.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx. There was no cost of products sold recognized in the three months ended
March 31, 2019, as IngenioRx began its operations during the second quarter of 2019.
Our selling, general and administrative expense 	increased 	primarily due to the reinstatement of the HIP Fee for 2020, and to a lesser extent, increased spend to
support growth in our businesses.
Our selling, general and administrative expense ratio decreased due to the growth in operating revenue. This decrease was partially offset by the reinstatement
of the HIP Fee for 2020 and increased spend to support growth in our businesses.
Our effective income tax rate 	increased 	primarily due to the reinstatement of the non-tax deductible HIP Fee for 2020, which resulted in additional income tax
expense of $87.
Our net income as a percentage of total revenue 	decreased 	during the three months ended March 31, 	2020 	as compared to the three months ended March 31,
2019 	as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles, or GAAP. We
also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among
periods. We define operating revenue as premium income, product revenue and administrative fees and other revenue. Operating gain is calculated as total
operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net
realized (losses) gains on financial instruments, impairment losses recognized in income, interest expense, amortization of other intangible assets, loss (gain) on
extinguishment of debt or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating
segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment
performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be
considered in isolation or as a substitute for income before income tax expense, net income or EPS, prepared in accordance with GAAP, and may not be
comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total
revenue included in the consolidated statements of income and a reconciliation of reportable segments’ operating gain to income before income tax expense, see
Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Beginning in 2020, IngenioRx meets the quantitative thresholds for a reportable segment and the results of our operations are now described through four
reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. For additional information, see Note 15, “Segment
Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-46-

-- 50 of 97 --

The following table presents a summary of the reportable segment financial information for the 	three 	months ended 	March 31, 2020 	and 	2019:
Three Months Ended
March 31
2020 	2019 	1 	$ Change 	% Change
Operating Revenue
Commercial & Specialty Business 	$ 	9,361 	$ 	9,392 	$ 	(31) 	(0.3)%
Government Business 	17,466 	14,925 	2,541 	17.0 	%
IngenioRx 	5,197 	— 	5,197 	NM
Other 	1,027 	548 	479 	87.4 	%
Eliminations 	(3,603) 	(477) 	(3,126) 	NM
Total operating revenue 	$ 	29,448 	$ 	24,388 	$ 	5,060 	20.7 	%
Operating Gain (Loss)
Commercial & Specialty Business 	$ 	1,420 	$ 	1,598 	$ 	(178) 	(11.1)%
Government Business 	411 	374 	37 	9.9 	%
IngenioRx 	349 	— 	349 	NM
Other 	14 	(32) 	46 	NM
Operating Margin
Commercial & Specialty Business 	15.2% 	17.0% 	(180)bp
Government Business 	2.4% 	2.5% 	(10)bp
IngenioRx 	6.7% 	—% 	NM
1 	During the second quarter of 2019, we reclassified DBG from our Government Business segment to our Other segment to reflect changes in how our segments are being
managed. Accordingly, certain amounts for the 	three 	months ended 	March 31, 2019 	have been reclassified to conform to the current year presentation for comparability.
Three Months Ended March 31, 2020 	Compared to the 	Three Months Ended March 31, 2019
Commercial & Specialty Business
Operating revenue 	decreased 	due to membership declines in our Individual and Local group fully-insured businesses and the absence of pharmacy
administrative fee revenue that is now recognized within the IngenioRx segment. These decreases were partially offset by the rate increases designed to cover
overall cost trends and the impact of the HIP Fee reinstatement for 2020.
The decrease in operating gain was primarily driven by margin normalization in our Individual business and the shift of pharmacy earnings to our IngenioRx
segment. The decrease was further due to the leap year impact of an extra day of claims in the three months ended March 31, 2020. These decreases were partially
offset by growth in our value-added services.
Government Business
Operating revenue 	increased 	primarily due to higher premium revenue as a result of organic growth, acquisitions and new expansions in our Medicaid
business and membership growth in our Medicare business. The increase in premium revenue was further attributable to rate increases designed to cover overall
cost trends and the HIP Fee reinstatement for 2020.
The increase in operating gain was primarily driven by premium rate adjustments and membership growth in our Medicaid business, as well as the impact of
the HIP Fee reinstatement for 2020. These increases in operating gain were partially offset by an increase in selling, general and administrative spend to support
growth in our businesses and the leap year impact of an extra day of claims in the three months ended March 31, 2020.
-47-

-- 51 of 97 --

IngenioRx
Operating revenue and operating gain increased as a result of IngenioRx commencing operations during the second quarter of 2019. Operating revenue
represents product revenues from services performed for our fully-insured Anthem health plans and self-funded customers and external customers outside of the
health plans we own. Product revenues and cost of goods sold for Anthem health plans are eliminated in consolidation. Operating gain represents operating
revenue less cost of products sold and selling, general and administrative expenses.
Other
Operating revenue increased primarily due to higher administrative fees and other revenue from services performed by DBG in certain markets and our
acquisition of Beacon in February 2020.
The increase in operating gain was due to growth in value-added services performed by DBG for our other segments.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important
accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income
taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our 	2019 	Annual
Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year
ended 	December 31, 2019, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations.” As of 	March 31, 2020, our critical accounting policies and estimates have not changed from those described in our
2019 	Annual Report on Form 10-K, except for the policies related to investments and receivables, which changed as a result of the adoption of a new accounting
pronouncement.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to
medical claims payable are discussed in the references cited above. As of 	March 31, 2020, our critical accounting policies and estimates related to medical claims
payable have not changed from those described in our 	2019 	Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical
claims payable for the 	three months ended 	March 31, 2020 	and 	2019, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements
included in Part I, Item 1 of this Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the
three months ended March 31, 2020 	and 	2019, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit
costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing
patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by
Changes in Key Assumptions
Three Months Ended
March 31
2020 	2019
Assumed trend factors 	$ 	510 	$ 	345
Assumed completion factors 	190 	110
Total 	$ 	700 	$ 	455
The favorable development recognized in the 	three months ended March 31, 2020 	and 	2019 	resulted primarily from trend factors in late 	2019 	and late 	2018,
respectively, developing more favorably than originally expected. Favorable
-48-

-- 52 of 97 --

development in the completion factors resulting from the latter parts of 	2019 	and 	2018 	developing faster than expected also contributed to the favorability.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 	64.7% 	for both the 	three months ended March 31,
2020 	and 	2019. This ratio serves as an indicator of claims processing speed whereby claims were processed at approximately the same speed during the three
months ended March 31, 2020 and 2019.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies
in the current period in order to demonstrate the development of the prior year reserves. For the 	three months ended March 31, 2020, this metric was 	8.8%, largely
driven by favorable trend factor development at the end of 	2019 	as well as favorable completion factor development from 2019. For the 	three months ended March
31, 2019, this metric was 	6.7%, largely driven by favorable trend factor development at the end of 	2018 	as well as favorable completion factor development from
2018.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of
redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our
prior year estimate of incurred medical claims and the consistency in our methodology. For the 	three months ended March 31, 2020, this metric was 	0.9%, which
was calculated using the redundancy of 	$700. For the 	three months ended March 31, 2019, the comparable metric was 	0.7%, which was calculated using the
redundancy of 	$455. We believe these metrics demonstrate a generally consistent level of reserve conservatism.
Investments
On January 1, 2020, we adopted Accounting Standards Update No. 2016-13, 	Financial Instruments - Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, 	or ASU 2016-13. The amendments in ASU 2016-13 replaced the incurred loss model for measuring expected credit losses and
require expected losses on available-for-sale fixed maturity securities to be recognized through an allowance for credit losses rather than as reductions in the
amortized cost of the securities. There were no other changes to our accounting policy for investments, as disclosed in our Annual Report on Form 10-K for the
year ended December 31, 2019. For additional information, see Note 4, “Investments” of the Notes to Consolidated Financial Statements included in Part I, Item 1
of this Form 10-Q.
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the global economy, causing market instability and significantly
decreasing the worldwide demand for energy. We regularly evaluate our fixed maturity securities for declines and impairment, as well as industry risk, and as a
result of our evaluation, we recognized a $49 credit loss allowance for our energy sector fixed maturity securities for the three months ended March 31, 2020. At
March 31, 2020, we held $888 of these securities, which have the potential to be further impaired if oil and natural gas prices stay at current levels or further
decline. At March 31, 2020, we also held $249 of equity investments in certain energy sector joint ventures, for which the fair value is estimated based on each
security’s current condition and future cash flow projections. Given the uncertainty of changes in market conditions, there is a risk that declines in fair value of
these investments may occur in the near future and further impairment losses may need to be recorded.
Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which
approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive
financial information from the companies. Given the recent market volatility, there is a risk that the value of some of these investments may decline in future
periods.
Additional discussion regarding the impact of COVID-19 on our business, cash flows, financial condition and results of operations can be found elsewhere in
this MD&A.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were adopted and new accounting pronouncements that were issued during the 	three months
ended March 31, 2020, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of
Presentation and Significant Accounting Policies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-49-

-- 53 of 97 --

Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or
maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash
disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings,
acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the
amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the economy, causing market instability and increasing unemployment in
the United States. While the full impact of COVID-19 on our business is currently uncertain, it could have a material adverse effect on our claim payments,
collection of our premiums, product or administrative fee revenues, investments and our ability to access credit. Additional discussion regarding the impact of
COVID-19 can be found elsewhere in this MD&A.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital
Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 	2019 	Annual
Report on Form 10-K.
For additional information regarding our sources and uses of capital during the 	three 	months ended 	March 31, 2020, see Note 5, “Derivative Financial
Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock - 	Use of Capital - Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity
A summary of our major sources and uses of cash and cash equivalents for the 	three months ended March 31, 2020 	and 	2019 	is as follows:
Three Months Ended
March 31 	2020 vs. 2019
2020 	2019 	Change
Sources of Cash:
Net cash provided by operating activities 	$ 	2,515 	$ 	1,630 	$ 	885
Issuances of commercial paper and short- and long-term debt, net of repayments 	1,528 	67 	1,461
Proceeds from issuance of common stock under employee stock plans 	44 	76 	(32)
Other sources of cash, net 	— 	28 	(28)
Total sources of cash 	4,087 	1,801 	2,286
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions 	(571) 	(440) 	(131)
Purchases of subsidiaries, net of cash acquired 	(1,908) 	— 	(1,908)
Repurchase and retirement of common stock 	(529) 	(294) 	(235)
Purchases of property and equipment 	(204) 	(234) 	30
Cash dividends 	(240) 	(206) 	(34)
Other uses of cash, net 	(225) 	(78) 	(147)
Total uses of cash 	(3,677) 	(1,252) 	(2,425)
Effect of foreign exchange rates on cash and cash equivalents 	(2) 	(1) 	(1)
Net increase in cash and cash equivalents 	$ 	408 	$ 	548 	$ 	(140)
The 	increase 	in cash provided by operating activities was 	primarily attributable to higher premium receipts as a result of the HIP Fee reinstatement in 2020 as
well as other changes in working capital.
-50-

-- 54 of 97 --

Other significant changes in sources or uses of cash year-over-year included increases in cash paid for acquisitions, cash paid for repurchase and retirement of
common stock and receipt of net proceeds from the issuances of commercial paper and short- and long-term debt.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity
securities of 	$26,301 	at 	March 31, 2020. Since 	December 31, 2019, total cash, cash equivalents and investments in fixed maturity and equity securities 	increased
by 	$174, primarily due to cash generated from operations and net proceeds from borrowings. These increases were partially offset by cash paid for acquisitions,
common stock repurchases, cash dividends paid to shareholders and purchases of property and equipment.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be
paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from
GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
undertakings to regulatory authorities, including requirements to maintain certain capital levels in certain of our subsidiaries.
At 	March 31, 2020, we held 	$1,689 	of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including
investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and
interest payments.
Debt
Periodically, we access capital markets and issue debt, or Notes, for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or
for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a
Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 10, “Debt” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of
this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I,
Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-
term borrowings, current portion of long-term debt, long-term debt, less current portion and lease liabilities. We believe our debt-to-capital ratio assists investors
and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio
that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated
debt-to-capital ratio was 	41.7% 	and 	39.5% 	as of 	March 31, 2020 	and 	December 31, 2019, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best
Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and
results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Future Sources and Uses of Liquidity
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the global economy and caused increased volatility in the securities and
credit markets. While the full impact of COVID-19 on our business is currently uncertain, it could have a material adverse effect on our financial condition and our
liquidity.
We have taken several recent actions to preserve our liquidity and financial flexibility. As a precautionary measure, we borrowed $300 on our senior revolving
credit facility in March 2020. This $300 was repaid in April 2020. Should commercial paper issuance become unavailable, we intend to use a combination of cash
on hand and/or our senior revolving credit facilities, which provide for combined credit up to $3,500, to redeem any outstanding commercial paper upon maturity.
In 	addition, in the second quarter of 2020, we expect to extend the term of our 364-day senior revolving credit facility to expire in June 2021.
-51-

-- 55 of 97 --

While there is no assurance in the current economic environment, we believe the lenders participating in our senior credit facilities, if market conditions allow,
will be willing to provide financing in accordance with their legal obligations.
Other measures we have taken include reducing our discretionary spending and temporarily suspending our share repurchase activity. To increase our cash on
hand, we are delaying our quarterly estimated federal income tax payments normally due during the second quarter of 2020 until July 15, 2020, as provided for by
IRS Notice 2020-23. We are also delaying certain payroll tax payments as permitted by the CARES Act. We may take additional actions going forward to
maximize our liquidity, including increasing our borrowings from existing or new Federal Home Loan Bank memberships and other available borrowings. We will
continue to monitor the market conditions and act in a prudent manner. Additional discussion regarding the impact of COVID-19 can be found elsewhere in this
MD&A.
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt
or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds
from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of
credit to our subsidiaries and the financing of possible acquisitions or business expansions.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at 	March 31, 2020, see Note 4, “Investments,” Note 5, “Derivative Financial
Instruments,” Note 10, “Debt” and Note 12, “Capital Stock - 	Use of Capital - Dividends and Stock Repurchase Program” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
Risk-Based Capital
Our regulated subsidiaries’ states of domicile have statutory risk-based capital, or RBC, requirements for health and other insurance companies and health
maintenance organizations largely based on the National Association of Insurance Commissioners, or NAIC, RBC Model Act. These RBC requirements are
intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for
calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an
individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance
department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of 	December 31,
2019, which was the most recent date for which reporting was required, were in excess of all mandatory RBC requirements. In addition to exceeding the RBC
requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net equity requirements
applicable to certain of our California subsidiaries.
For additional information, see Note 21, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31,
2019 	included in our 	2019 	Annual Report on Form 10-K.
Contractual Obligations and Commitments
We believe that funds from future operating cash flows, cash and investments and funds available under our 5-year and 364-day senior revolving credit
facilities and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic
transactions.
There have been no material changes to our Contractual Obligations and Commitments disclosure in our 	2019 	Annual Report on Form 10-K other than our
entry into a vendor agreement for information technology infrastructure and related management and support services and an increase in our borrowings. For
additional information regarding our estimated contractual obligations and commitments, see Note 5, “Derivative Financial Instruments,” Note 10, “Debt,” and the
“Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11, “Commitments and Contingencies,” of the Notes to Consolidated
Financial Statements included in Part I, Item 1 of this Form 10-Q.
-52-

-- 56 of 97 --

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,”
“will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking
statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans,
objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to
certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements
that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with
the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or
circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public
health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium
rates, including regulatory approval for and implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient
Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, and the ultimate
outcome of legal challenges to the ACA; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment
portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential
information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare
and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services, or CMS, Star ratings and other quality scores and funding risks with respect to revenue received
from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations,
audits or reviews; the ultimate outcome of litigation between Cigna Corporation and us related to the merger agreement between the parties and the potential for
such litigation to cause us to incur substantial additional costs, including potential settlement and judgment costs; risks and uncertainties related to our pharmacy
benefit management, or PBM, business including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.;
medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately
support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of
capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and
other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the
effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information
systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; the impact of international laws and regulations; changes
in U.S. tax laws; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent or discourage
takeovers and business combinations.
-53-

-- 57 of 97 --

ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 	2019 	Annual Report on
Form 10-K. There have been no material changes to any of these risks since 	December 31, 2019.
ITEM 4. 	CONTROLS AND PROCEDURES
We carried out an evaluation as of 	March 31, 2020, under the supervision and with the participation of our management, including our Chief Executive Officer
and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the
Securities Exchange Act of 1934, as amended, or the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated
subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file
or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as
appropriate to allow timely decisions regarding required disclosures.
During the three months ended March 31, 2020, we implemented certain additional controls associated with our IngenioRx PBM business. Other than these
new controls, there have been no changes in our internal control over financial reporting that occurred during the three months ended 	March 31, 2020 	that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
For information regarding legal proceedings at 	March 31, 2020, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note
11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
ITEM 1A. 	RISK FACTORS
Except as set forth below, there have been no material changes to the risk factors disclosed in our 	2019 	Annual Report on Form 10-K.
The following risk factor has been added:
The outbreak of the COVID-19 pandemic and measures taken to prevent its spread are adversely affecting our business in a number of ways, and we
are unable to predict the full extent of those impacts on our business, cash flows, financial condition and results of operations, but the impact could
be material.
The ongoing COVID-19 pandemic has caused illness, deaths, quarantines, business and school shutdowns, reductions in business activity, travel and
financial transactions, unemployment, labor shortages, supply chain interruptions and overall economic and financial market instability, and it
underscores and may heighten certain risks we face in our business, including those discussed in our 2019 Annual Report on Form 10-K.
We are closely monitoring developments related to the COVID-19 pandemic to assess its ongoing impact on our business. While we expect the
impacts of COVID-19, and the actions taken to contain its spread or address its impacts, to have an adverse effect on our business, cash flows, financial
condition and results of operations, the extent of those impacts will depend on future developments, which are highly uncertain and cannot be predicted at
this time, including, but not limited to, the transmission rate, duration and spread of the outbreak, its severity, the extent and effectiveness of the actions
taken to contain the spread of the virus and address its impacts, and how quickly and to what extent normal economic and operating conditions can
resume. Factors that could negatively
-54-

-- 58 of 97 --

impact our ability to operate successfully during or following the COVID-19 pandemic, or that could otherwise significantly adversely impact and disrupt
our business, cash flows, financial condition and results of operations include, but are not limited to, the following:
• 	Increased healthcare costs due to higher utilization rates of medical facilities and services, medical expenses and other increases in associated
hospital and pharmaceutical costs. We have begun to offer our members expanded benefit coverage, such as providing full coverage for COVID-
19 testing and treatment, and governmental action has required, and may continue to require, us to provide additional coverage.
• 	A reduction in enrollment in our health benefits and pharmacy benefit management products and services, or a change in membership mix to less
profitable lines of business, as a result of reductions in workforce by existing customers and other impacts of an economic downturn.
• 	Cash flow volatility or shortfalls caused by an increase in delayed, delinquent or non-collectable payments from customers and government
payers.
• 	Reductions in our operating effectiveness as our employees work from home or otherwise are impacted by COVID-19. We have transitioned
nearly all of our employee population to a remote work environment in an effort to mitigate the spread of COVID-19, which may exacerbate
certain risks to our business, including an increased demand for information technology resources, increased risk of phishing and other
cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential
information about us, our members or other third parties.
• 	Disruptions in our normal business operations due to disruptions in public and private infrastructure, 	including communications, financial
services and supply chains.
• 	Loss of functionality due to the disruption of services provided to us by third-party vendors, including as a result of financial difficulties
experienced by such vendors and the impact of vendor employees working from home or otherwise being impacted by COVID-19.
• 	Increased cost of capital and limited ability to access the capital markets due to disruption and volatility in global financial markets or a
downgrade in our credit rating.
• 	A further decrease in the value of our investments, which may result in additional losses charged to income.
• 	An increase in our effective income tax rate due to the impacts of COVID-19 on our income and other factors described above and the non-tax
deductibility of the HIP Fee.
For more information on how these and other risks may further affect our business, please see Part I, Item 1A, “Risk Factors” in our 2019 Annual Report on
Form 10-K.
-55-

-- 59 of 97 --

ITEM 2. 	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
January 1, 2020 to January 31, 2020 	509,949 	$ 	298.71 	509,300 	$ 	3,640
February 1, 2020 to February 29, 2020 	671,852 	278.76 	670,900 	3,453
March 1, 2020 to March 31, 2020 	1,135,798 	261.46 	740,058 	3,263
2,317,599 	1,920,258
1 	Total number of shares purchased includes 397,341 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise
or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated
statements of shareholders’ equity are shown net of these shares purchased.
2 	Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of
Directors evaluates periodically. During the three months ended 	March 31, 2020, we repurchased 	1,920,258 	shares at a cost of $529 under the program,
including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The Board of
Director’s most recent authorized increase to the program was 	$5,000 	on December 7, 2017. No duration has been placed on our common stock repurchase
program, and we reserve the right to discontinue the program at any time.
ITEM 3. 	DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. 	MINE SAFETY DISCLOSURES
None.
ITEM 5. 	OTHER INFORMATION
None.
-56-

-- 60 of 97 --

ITEM 6. 	EXHIBITS
Exhibit
Number 	Exhibit
3.1 	Amended and Restated Articles of Incorporation of the Company, as amended and restated effective May 15, 2019, incorporated by
reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 15, 2019.
3.2 	Bylaws of the Company, as amended effective April 8, 2020, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on
Form 8-K filed on April 8, 2020.
4.7 	Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the
rights of holders of long-term debt of the Company or its subsidiaries.
4.8 	Description of the Company’s Securities Registered Pursuant to Section 12 of the Exchange Act.
10.2 	* 	(l) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2020.
* 	(m) 	Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2020.
* 	(n) 	Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2020.
31.1 	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.
32.2 	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
101 	The following material from Anthem, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline
XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income;
(iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated
Statements of Shareholders’ Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the
Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104 	Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
* 	Indicates management contracts or compensatory plans or arrangements.
-57-

-- 61 of 97 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
ANTHEM, INC.
Registrant
Date: April 29, 2020 	By: 	/S/ JOHN 	E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
Date: April 29, 2020 	By: 	/S/ RONALD 	W. PENCZEK
Ronald W. Penczek
Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
-58-

-- 62 of 97 --

Exhibit 4.8
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF
1934
The common stock of Anthem, Inc. (“Anthem,” “we,” “our,” or “us”) is the only class of securities registered under Section 12 of the Securities Exchange Act of
1934, as amended.
The following is a summary of the general terms and provisions of our common stock. This summary does not purport to be complete and is subject to and
qualified by reference to our amended and restated articles of incorporation, as amended (our “articles of incorporation”) and our bylaws, as amended (our
“bylaws”), both of which are filed as exhibits to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”).
For additional information, please read our articles of incorporation, our bylaws and the applicable provisions of the Indiana Business Corporation Law, as
amended (the “IBCL”).
General
We are authorized to issue up to 900,000,000 shares of common stock, par value $0.01 per share, as well as up to 100,000,000 shares of preferred stock,
without par value. We have no shares of preferred stock issued or outstanding.
Each holder of our common stock is entitled to one vote per share of record on all matters to be voted upon by the shareholders. Holders do not have
cumulative voting rights in the election of directors or any other matter.
Subject to the preferential rights of the holders of any preferred stock that may at the time be outstanding, each share of common stock will entitle the holder
of that share to an equal and ratable right to receive dividends or other distributions (other than purchases, redemptions or other acquisitions of shares by us) if
declared from time to time by our board of directors and if there are sufficient funds to legally pay a dividend.
In the event of our liquidation, dissolution or winding up, whether voluntary or involuntary, the holders of common stock will be entitled to share ratably in
all assets remaining after payments to creditors and after satisfaction of the liquidation preference, if any, of the holders of any preferred stock that may at the time
be outstanding.
Holders of common stock have no preemptive or redemption rights and will not be subject to further calls or assessments by us.
Our common stock trades on the New York Stock Exchange under the symbol “ANTM.” Computershare Trust Company, N.A. is the registrar, transfer
agent, conversion agent and dividend disbursing agent for the common stock.
Authorized But Unissued Shares
Indiana law does not require shareholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of
corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate acquisitions. One of the effects of the existence
of authorized but unissued shares may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render
more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of
current management and possibly deprive the shareholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices. In
addition, depending on the rights prescribed for any series of preferred stock that may be issued, the issuance of preferred stock could have an adverse effect on the
voting power of the holders of common stock or could impose restrictions upon the payment of dividends and other distributions to the holders of common stock.
Limitations on Ownership of Our Common Stock in Articles of Incorporation
As required under our licenses with the Blue Cross and Blue Shield Association (“BCBSA”), our articles of incorporation contain certain limitations on the
ownership of our common stock. Our articles of incorporation provide that no person may beneficially own shares of voting capital stock in excess of specified
ownership limits, except with the prior approval of a majority of the “continuing directors.” The ownership limits, which may not be exceeded without the prior
approval of the BCBSA, are the following:
• 	for any institutional investor (as defined in our articles of incorporation), one share less than 10% of our outstanding voting securities;
1

-- 63 of 97 --

Exhibit 4.8
• 	for any non-institutional investor (as defined in our articles of incorporation), one share less than 5% of our outstanding voting securities; and
• 	for any person, one share less than the number of shares of our common stock or other equity securities (or a combination thereof) representing a
20% ownership interest in us.
Any transfer of stock that would result in any person beneficially owning shares of capital stock in excess of any ownership limit will result in the intended
transferee acquiring no rights in the shares exceeding such ownership limit (with certain exceptions) and the person’s excess shares will be deemed transferred to
an escrow agent to be held until the shares are transferred to a person whose ownership of the shares will not violate the ownership limit.
Certain Other Provisions of Our Articles of Incorporation and Bylaws
Certain other provisions of our articles of incorporation and bylaws may delay or make more difficult unsolicited acquisitions or changes of control of us.
These provisions could have the effect of discouraging third parties from making proposals involving an unsolicited acquisition or change in control of us, although
these proposals, if made, might be considered desirable by a majority of our shareholders. These provisions may also have the effect of making it more difficult for
third parties to cause the replacement of the current management without the concurrence of the board of directors. These provisions include:
• 	the division of the board of directors into three classes serving staggered terms of office of three years;
• 	provisions limiting the maximum number of directors to 19;
• 	provisions requiring that, except in certain limited circumstances, the filling of any vacancy on the board of directors must be approved by a majority of
continuing directors; and
• 	requirements for advance notice for raising business or making nominations at shareholders’ meetings.
Our bylaws establish an advance notice procedure with regard to business to be brought before an annual or special meeting of shareholders and advance
notice and proxy access procedures with regard to the nomination of candidates for election as directors, other than by or at the direction of the board of directors.
Although our bylaws do not give the board of directors any power to approve or disapprove shareholder nominations for the election of directors or proposals for
action, they may have the effect of precluding a contest for the election of directors or the consideration of shareholder proposals if the established procedures are
not followed, and of discouraging or deterring a third party from conducting a solicitation of proxies to elect its own slate of directors or to approve its proposal
without regard to whether consideration of those nominees or proposals might be harmful or beneficial to us and our shareholders.
In addition, our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (a) any derivative
action or proceeding brought on our behalf, (b) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or
agents to us or certain specified constituents of ours, (c) any action asserting a claim arising pursuant to any provision of the IBCL or our articles of incorporation
or bylaws, or (d) any action asserting a claim governed by the internal affairs doctrine, will be, to the fullest extent permitted by law, the Marion Superior Court in
Marion County, Indiana or, if the Marion Superior Court lacks jurisdiction, the United States District Court for the Southern District of Indiana.
Amendment and Repeal of Bylaws
Our articles of incorporation and bylaws provide that the bylaws may be altered, amended or repealed by either (1) the affirmative vote of a majority of the
entire number of directors, or (2) except for certain provisions of the bylaws, the affirmative vote, at a shareholder meeting, of at least a majority of the votes
entitled to be cast by the holders of the outstanding shares of all classes of our stock entitled to vote generally in the election of directors, considered for this
purpose as a single voting group.
2

-- 64 of 97 --

Exhibit 4.8
Certain Provisions of the Indiana Business Corporation Law
As an Indiana corporation, we are governed by the IBCL. The following are some of the more significant provisions of the IBCL that may delay, prevent or
make more difficult certain unsolicited acquisitions or changes of control of us. These provisions also may have the effect of preventing changes in our
management. It is possible that these provisions could make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best
interest.
Control Share Acquisitions. 	Under Chapter 42 of the IBCL, an acquiring person or group who acquires, directly or indirectly, ownership of, or the power to
direct the exercise of voting power with respect to, issued and outstanding “control shares” in an “issuing public corporation” may not exercise voting rights on any
control shares unless these voting rights are conferred by a majority vote of the disinterested shareholders of the issuing public corporation at a special meeting of
those shareholders held upon the request and at the expense of the acquiring person. If the acquiring person has acquired control shares with a majority of the
voting power and the control shares are accorded full voting rights by the disinterested shareholders, the disinterested shareholders of the issuing public corporation
have dissenters’ rights to receive the fair value of their shares pursuant to Chapter 44 of the IBCL. We are an “issuing public corporation” as defined under Chapter
42.
Under Chapter 42, “control shares” means shares acquired by a person that, when added to all other shares of the issuing public corporation owned by that
person or in respect to which that person may exercise or direct the exercise of voting power, would otherwise entitle that person to exercise voting power of the
issuing public corporation in the election of directors within any of the following ranges: (i) one-fifth or more but less than one-third; (ii) one-third or more but less
than a majority; or (iii) a majority or more.
Chapter 42 does not apply if, before a control share acquisition is made, the corporation’s articles of incorporation or bylaws, including a bylaw adopted by
the corporation’s board of directors, provide that they do not apply. Our bylaws provide that we are not subject to Chapter 42; however, our board of directors
could amend our bylaws to rescind our election to opt out of Chapter 42.
Certain Business Combinations. 	Chapter 43 of the IBCL restricts the ability of an Indiana corporation that has 100 or more shareholders to engage in any
combinations with an “interested shareholder” for five years after the date the shareholder became an “interested shareholder” (such date, the “share acquisition
date”), unless the combination or the purchase of shares by the interested shareholder on the interested shareholder’s share acquisition date is approved by the
board of directors of the corporation before the share acquisition date. If such prior approval is not obtained, the interested shareholder may effect a combination
after the five-year period only if that shareholder receives approval from a majority of the disinterested shareholders or the offer meets specified fair price criteria.
For purposes of Chapter 43, “interested shareholder” means any person, other than the corporation or its subsidiaries, who is (1) the beneficial owner,
directly or indirectly, of 10% or more of the voting power of the outstanding voting shares of the corporation or (2) an affiliate or associate of the corporation,
which at any time within the five-year period immediately before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting
power of the then outstanding shares of the corporation.
Chapter 43 does not apply to corporations that elect not to be subject to Chapter 43 in an amendment to their articles of incorporation approved by a majority
of the disinterested shareholders. That amendment, however, cannot become effective until 18 months after its passage and would apply only to share acquisitions
occurring after its effective date. Our articles of incorporation do not exclude us from Chapter 43.
Mandatory Classified Board of Directors. Under Chapter 33 of the IBCL, a corporation with a class of voting shares registered with the SEC under
Section 12 of the Exchange Act must have a classified board of directors unless the corporation adopts a bylaw expressly electing not to be governed by this
provision. Although our articles of incorporation and bylaws provide for a classified board of directors so long as we are required to do so under our licenses with
the BCBSA, we adopted an amendment to our bylaws electing not to be subject to this mandatory requirement effective July 29, 2009.
3

-- 65 of 97 --

Exhibit 4.8
Unanimous Written Consent of Shareholders. Under Chapter 29 of the IBCL, as well as our articles of incorporation and our bylaws, any action required or
permitted to be taken by the holders of common stock may be effected only at an annual meeting or special meeting of such holders, and shareholders may act in
lieu of such meetings only by unanimous written consent.
4

-- 66 of 97 --

EXHIBIT 10.2(l)
Schedule A
Notice of Option Grant
Participant: 	[•]
Company: 	Anthem, Inc.
Notice: 	You have been granted the following nonqualified stock option to purchase shares of common stock of the Company in accordance
with the terms of the Plan and the attached Nonqualified Stock Option Award Agreement.
Plan: 	2017 Anthem Incentive Compensation Plan
Grant: 	Grant Date: [•]
Option Price per Share: $[•]
Number of Shares under Option: [•]
Exercisability: 	Subject to the terms of the Plan and this Agreement, your Option will become exercisable on and after the dates indicated below as to
the number of Shares set forth below opposite each such date, plus any Shares as to which your Option could have been exercised
previously but was not so exercised.
Shares 	Date
[•] 	[•]
[•] 	[•]
[•] 	[•]
In the event that a Change of Control (as defined in the Plan) occurs before your Termination, your Option will remain subject
to the terms of this Agreement, unless the successor company does not assume your Option. If a successor company does not assume
your Option, then your Option shall become fully exercisable immediately prior to the Change of Control.
Expiration Date: 	Your Option will expire ten years from the Grant Date, subject to earlier termination as set forth in the Plan and this Agreement.
Acceptance: 	In order to accept your Options, you must electronically accept this Agreement through the Company’s broker at any time within ninety
(90) days after the Grant Date. To effect your acceptance, please follow the instructions included with your grant materials. Acceptance
of the Agreement includes acceptance of the terms and conditions of the Plan. If you do not timely and electronically accept this
Agreement, this Agreement will be null and void as of the 90th day after the Grant Date and you will have no right or claim to the
Options described above.

-- 67 of 97 --

Nonqualified Stock Option Award Agreement
This Nonqualified Stock Option Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of
Option Grant attached as Schedule A hereto (the “Grant Notice”) is made between Anthem, Inc. (the “Company”) and the Participant set forth in the Grant Notice.
The Grant Notice is included in and made part of this Agreement.
1. 	Grant of the Option. Subject to the provisions of this Agreement and the provisions of the Plan, the Company hereby grants to the
Participant, pursuant to the Plan, the right and option (the “Option”) to purchase all or any part of the number of shares of common stock of the Company
(“Shares”) as set forth in the Grant Notice at an Option Price (“Option Price”) per share and on the other terms as set forth in the Grant Notice. This Option is
intended to be a nonqualified stock option for federal income tax purposes.
2. 	Method of Exercise of the Option.
(a) 	The Participant may exercise the Option, to the extent then exercisable, by delivering a notice to the Company’s captive
broker in a form specified or accepted by the captive broker, specifying the number of Shares with respect to which the Option is being exercised.
(b) 	At the time the Participant exercises the Option, the Participant shall pay the Option Price of the Shares as to which the
Option is being exercised and applicable taxes (i) in United States dollars by personal check, bank draft or money order; (ii) subject to such terms, conditions and
limitations as the Compensation Committee of the Board of Directors of the Company (“Committee”) may prescribe, by tendering (either by actual delivery or
attestation) unencumbered Shares previously acquired by the Participant having an aggregate Fair Market Value at the time of exercise equal to the total Option
Price of the Shares for which the Option is so exercised; (iii) subject to such terms, conditions and limitations as the Committee may prescribe, a cashless (broker-
assisted) exercise that complies with all applicable laws; or (iv) by a combination of the consideration provided for in the foregoing clauses (i), (ii) and (iii).
3. 	Termination. The Option shall terminate upon the Participant’s Termination for any reason and no Shares may thereafter be
purchased under the Option except as provided below. Notwithstanding anything contained in this Agreement, (i) a Participant who is in a position of Vice
President or above must give at least 30 days advance written notice of his Termination due to resignation (including Retirement) in order for the Participant to
exercise the Option for any period that may apply below and (ii) in no event shall the Option be exercisable after the Expiration Date. If less than 30 days advance
written notice is given, the Option shall be immediately canceled, including the portion of the Option that is otherwise exercisable.
(a) 	Retirement. 	If the Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as the
Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service or after attaining age sixty-five (65)), the Option shall
continue to become exercisable according to the schedule set forth in the Grant Notice; 	provided 	that the Option shall terminate on the five-year anniversary of the
date of the Participant’s Retirement but not later than the Expiration Date noted on the attached Schedule A; 	provided, further, 	that if the Participant’s Termination
is due to Retirement during the calendar year of the Grant Date, the Option shall be immediately terminated on a pro-rata basis, measured by the number of
completed full months in that calendar year during which the Participant was employed by the Company or an Affiliate (e.g., if the Participant’s Retirement occurs
in September, 33.3% (or 4/12) of the Option shall be immediately terminated), and the non-terminated portion of the Option shall continue to become exercisable
according to the schedule set forth in the Grant Notice.1
(b) 	Death and Disability. 	If the Participant’s Termination is due to the Participant’s death or Disability (for purposes of this
Agreement, as defined in the applicable Anthem Long-Term Disability Plan), the Option shall immediately become fully exercisable and shall terminate on the
five-year anniversary of the date of such Termination but not later than the Expiration Date noted on the attached Schedule A.
1 	This retirement provision is deleted in non-annual retention grants.

-- 68 of 97 --

(c) 	Termination without Cause. 	Unless Sections 3(a) or 3(e) are applicable, if the Participant’s Termination is by the Company
or an Affiliate without Cause (for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Anthem HR Corrective Action
Policy and if the Participant participates in the Anthem, Inc. Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement or the Key Sales
Associate Agreement also as defined in that plan or agreement) or voluntarily by the Participant, the following shall apply:
(i) 	Unless clause (ii) applies, the Option, to the extent fully exercisable as of the date of such Termination, shall thereafter only
be exercisable for a period of ninety (90) days from the date of such Termination, but not later than the Expiration Date noted on the attached Schedule A.
(ii) 	If the Participant is receiving severance under the Agreement Plan, the Anthem Supplemental Unemployment Benefit Plan,
the Anthem Excess Termination Benefit Plan, the Key Associate Agreement or the Key Sales Associate Agreement and any portion of the Option remains
unexercisable as of the Participant’s Termination, the Option shall continue to become exercisable through the earlier of (A) the last day of the period for
which the Participant is receiving severance or (B) the last day of the schedule set forth in the Grant Notice. The Option shall be exercisable for a period
of ninety (90) days from the date the severance period ends, but not later than the Expiration Date noted on the attached Schedule A.
(d) 	Cause. 	If the Participant’s Termination is for Cause, even if on the date of such Termination the Participant has met the
definition of Retirement or Disability, then the portion of the Option that has not been exercised shall immediately terminate.
(e) 	Termination after Change of Control. 	If after a Change of Control the Participant’s Termination is (i) by the Company or an
Affiliate without Cause or (ii) if the Participant participates in the Executive Agreement Plan, by the Participant for Good Reason (as defined in the Executive
Agreement Plan), the Option shall immediately become fully exercisable and shall terminate on the five-year anniversary of the date of such Termination but not
later than the Expiration Date noted on the attached Schedule A.
4. 	Transferability of the Option. The Option shall not be transferable or assignable by the Participant except as provided in this Section 4
and the Option shall be exercisable, during the Participant’s lifetime, only by him/her or, during periods of legal disability, by his guardian or other legal
representative. No Option shall be subject to execution, attachment, or similar process. The Participant shall have the right to appoint any individual or legal entity
in writing, on a Designation of Beneficiary form as his/her beneficiary to receive any Option (to the extent not previously terminated or forfeited) under this
Agreement upon the Participant’s death. Such designation under this Agreement may be revoked by the Participant at any time and a new beneficiary may be
appointed by the Participant by execution and submission to the Company, or its designee, of a revised Designation of Beneficiary form to this Agreement. In order
to be effective, a designation of beneficiary must be completed by the Participant on the Designation of Beneficiary form and received by the Company, or its
designee, prior to the date of the Participant’s death. If the Participant dies without such designation, the Option may be exercised only by the executor or
administrator of the Participant’s estate or by a person who shall have acquired the right to such exercise by will or by the laws of descent and distribution.
5. 	Taxes and Withholdings. At the time of receipt of Shares upon the exercise of all or any part of the Option, the Participant shall pay
to the Company in cash (or make other arrangements, in accordance with Article XVIII of the Plan, for the satisfaction of) any taxes of any kind required by law to
be withheld with respect to such Shares; 	provided, 	however, that pursuant to any procedures, and subject to any limitations as the Committee may prescribe and
subject to applicable law, the Participant may elect to satisfy, in whole or in part, such withholding obligations by (a) withholding Shares otherwise deliverable to
the Participant pursuant to the Option (provided, however, 	that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy required
Federal, state, local and non-United States withholding obligations using the minimum statutory withholding rates for Federal, state, local and/or non-U.S. tax
purposes, including payroll taxes, that are applicable to supplemental taxable income) and/or (b) tendering to the Company Shares owned by the Participant (or the
Participant and the Participant’s spouse jointly) based, in each case, on the Fair Market Value of the Shares on the payment date as determined by the Committee.
Any such election made by the Participant must be irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitations that
the Committee, in its sole discretion, deems appropriate.

-- 69 of 97 --

6. 	No Rights as a Shareholder. Neither the Participant nor any other person shall become the beneficial owner of the Shares subject to
the Option, nor have any rights to dividends or other rights as a shareholder with respect to any such Shares, until the Participant has actually received such Shares
following the exercise of the Option in accordance with the terms of the Plan and this Agreement.
7. 	Restrictive Covenants. For purposes of Sections 7, 8, 9, 10 and 11 of this Agreement, Company shall mean Anthem, Inc. and its
subsidiaries and affiliates. The Participant acknowledges that s/he has the right to consult with counsel at the Participant’s sole expense. As a condition to receipt of
the Option Grant made under this Agreement, which the Participant and the Company agree is fair and reasonable consideration, the Participant agrees as follows:
(a) 	Confidentiality.
(i) 	The Participant recognizes that the Company derives substantial economic value from information created and used in its
business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs, formulae, and equations;
product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the Company, its affiliates and any of its
customers, vendors, business partners or suppliers; profit margins and the prices and discounts the Company obtains or has obtained or at which it sells or
has sold or plans to sell its products or services (except for public pricing lists); manufacturing, assembling, labor and sales plans and costs; business and
marketing plans, ideas, or strategies; confidential financial performance and projections; employee compensation; employee staffing and recruiting plans
and employee personal information; and other confidential concepts and ideas related to the Company’s business (collectively, “Confidential
Information”). The Participant expressly acknowledges and agrees that by virtue of his/her employment with the Company, the Participant will have
access and will use in the course of the Participant’s duties certain Confidential Information and that Confidential Information constitutes trade secrets
and confidential and proprietary business information of the Company, all of which is the exclusive property of the Company. For purposes of this
Agreement, Confidential Information includes the foregoing and other information protected under the Indiana Uniform Trade Secrets Act (the “Act”), or
to any comparable protection afforded by applicable law, but does not include information that the Participant establishes by clear and convincing
evidence is or may become known to the Participant or to the public from sources outside the Company and through means other than a breach of this
Agreement. Notwithstanding the foregoing, in accordance with the Defend Trade Secrets Act of 2016, the Participant will not be held criminally or civilly
liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law;
or (B) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If the Participant files a lawsuit for retaliation by
the Company for reporting a suspected violation of law, the Participant may disclose the Company’s trade secrets to his/her attorney and use the trade
secret information in the court proceeding if the Participant (A) files any document containing the trade secret under seal; and (B) does not disclose the
trade secret, except pursuant to court order.
(ii) 	The Participant agrees that the Participant will not for himself or herself or for any other person or entity, directly or
indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential Information for the
benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce any document or tangible item
embodying or pertaining to any of the Confidential Information, except as required to perform the Participant’s duties for the Company or its affiliates; or
(C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to any third party any Confidential Information by
any communication, including oral, documentary, electronic or magnetic information transmittal device or media. Upon termination of employment, the
Participant shall return all Confidential Information and all other property of the Company. This obligation of non-disclosure and non-use of information
shall continue to exist for so long as such information remains Confidential Information. Provided, however, nothing in this Agreement prohibits or limits
the Participant from (i) reporting possible violations of federal securities law or regulation to any governmental agency or entity or (ii) receiving a
monetary award from the governmental agency or entity for the information reported.

-- 70 of 97 --

(b) 	Non-Competition. During any period in which the Participant is employed by the Company, and during a period of time
after the Participant’s termination of employment (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months
for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other
Participants, the Participant will not, without prior written consent of the Company, directly or indirectly seek or obtain a Competitive Position in a Restricted
Territory and perform a Restricted Activity with a Competitor, as those terms are defined herein.
(i) 	Competitive Position means any employment or performance of services with a Competitor (A) the same as or similar to
the services in which Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with Company, or (B) in
which the Participant will use any Confidential Information of the Company.
(ii) 	Restricted Territory means any geographic area in which the Company does business and in which the Participant
provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such business, within
the thirty-six (36) months prior to the Participant’s termination of employment from the Company.
(iii) 	Restricted Activity means any activity for which the Participant had responsibility for the Company within the thirty-six
(36) months prior to the termination of the Participant’s employment from the Company or about which the Participant had Confidential Information.
(iv) 	Competitor means any entity or individual (other than the Company or its affiliates) engaged in management of network-
based managed care plans and programs, or the performance of managed care services, health insurance, long term care insurance, dental, life or disability
insurance, behavioral health, vision, flexible spending accounts and COBRA administration or other products or services substantially the same or similar
to those offered by the Company while the Participant was employed, or other products or services offered by the Company within twelve (12) months
after the termination of Participant’s employment if the Participant had responsibility for, or Confidential Information about, such other products or
services while the Participant was employed by the Company.
(v) 	The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position that
consists of practicing law.
(c) 	Non-Solicitation of Customers. During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, consultant,
independent contractor, owner, agent, or in any other capacity, directly or indirectly, for a Competitor of the Company as defined in subsection (b) above: (i) solicit
business from any client or account of the Company or any of its affiliates with which the Participant had contact, participated in the contact, or responsibility for,
or about which the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, (ii) solicit business from
any client or account which was pursued by the Company or any of its affiliates and with which the Participant had contact, or responsibility for, or about which
the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, within the twelve (12) month period prior
to termination of employment. For purposes of this provision, an individual policyholder in a plan maintained by the Company or by a client or account of the
Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or
account subject to this restriction solely by reason of being such a policyholder or certificate holder.

-- 71 of 97 --

(d) 	Non-Solicitation of Employees. During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, independent
contractor, owner, agent, or in any other capacity, directly or indirectly solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any
non-Company affiliated entity, any person who on or during the six (6) months immediately preceding the date of such solicitation or hire is or was an officer or
employee of the Company, or whom the Participant was involved in recruiting while the Participant was employed by the Company.
(e) 	Non-Disparagement. The Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make
any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business
reputation of the Company’s directors, employees, officers and managers. Further, the Participant will not at any time make any verbal or written statement to any
media outlet regarding the Company.
8. 	Return of Consideration.
(a) 	If at any time a Participant breaches any provision of Section 7 or Section 11 then: (i) all unexercised Company stock options under
any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate; (ii) the Participant shall forfeit
any outstanding restricted stock or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of breach; and (iii) the
Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an option under a
Designated Plan within the 24 months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the exercise price,
and (B) for each share of restricted stock and/or performance stock that became vested under any Designated Plan within the 24 months prior to such breach, the
fair market value (on the date of vesting) of a Common Share. Any amount to be repaid pursuant to this Section 8 shall be held by the Participant in constructive
trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by the Participant to the Company
with interest from the date such Common Share was acquired or the share of restricted stock became vested, as the case may be, to the date of payment, at 120% of
the applicable six month short-term applicable federal rate. Any amount described in clauses (i) and (ii) that the Participant forfeits as a result of a breach of the
provisions of Sections 7 or 11 shall not reduce any money damages that would be payable to the Company as compensation for such breach.
(b) 	The amount to be repaid pursuant to this Section 8 shall be determined on a gross basis, without reduction for any taxes incurred, as
of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have the right to
offset such amount against any amounts otherwise owed to the Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit plan or
other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c) 	For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or long-term
incentive compensation plan.
9. 	Equitable Relief and Other Remedies. As a condition to this Agreement:
(a) 	The Participant acknowledges that each of the provisions of Section 7 and 8 of the Plan are reasonable and necessary to preserve the
legitimate business interests of the Company, its present and potential business activities and the economic benefits derived therefrom; that they will not prevent
him or her from earning a livelihood in the Participant’s chosen business and are not an undue restraint on the trade of the Participant, or any of the public interests
which may be involved.

-- 72 of 97 --

(b) 	The Participant agrees that beyond the amounts otherwise to be provided under the Plan and this Agreement, the Company will be
damaged by a violation of the terms of this Agreement and the amount of such damage may be difficult to measure. The Participant agrees that if the Participant
commits or threatens to commit a breach of any of the covenants and agreements contained in Sections 7 or 11 to the extent permitted by applicable law, then the
Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as required by law,
in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such breach would
cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Further, if the Participant violates Section 7 hereof the
Participant agrees that the period of violation shall be added to the period in which the Participant’s activities are restricted.
(c) 	Notwithstanding the foregoing, the Company will not seek injunctive relief to prevent a Participant residing in California from
engaging in post termination competition in California under Section 7(b) or (c) of this Agreement, provided that the Company may seek and obtain relief to
enforce Section 8 of this Agreement with respect to such Participants.
(d) 	The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration, scope, area
or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the parties agree that the maximum duration,
scope, area or activity restrictions reasonable and enforceable under such circumstances shall be substituted for the stated duration, scope, area or activity
restrictions to the maximum extent permitted by law. The parties further agree that the Company’s rights under Section 8 should be enforced to the fullest extent
permitted by law irrespective of whether the Company seeks equitable relief in addition to relief provided therein or if the arbitrator or court deems equitable relief
to be inappropriate.
10. 	Survival of Provisions. The obligations contained in Sections 7, 8, 9 and Section 11 shall survive the Termination of the
Participant’s employment with the Company and shall be fully enforceable thereafter.
11. 	Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), the
Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after
the termination of Participant’s employment for any reason, the Participant will respond and provide information with regard to matters in which the Participant
has knowledge as a result of the Participant’s employment with the Company, and will provide reasonable assistance to the Company, its affiliates and their
respective representatives in defense of any claims that may be made against the Company or its affiliates, and will assist the Company and its affiliates in the
prosecution of any claims that may be made by the Company or its affiliates, to the extent that such claims may relate to the period of the Participant’s employment
with the Company (or any predecessor); provided, that with respect to periods after the termination of the Participant’s employment, the Company shall reimburse
the Participant for any out-of-pocket expenses incurred in providing such assistance and if the Participant is required to provide more than ten (10) hours of
assistance per week after his termination of employment then the Company shall pay the Participant a reasonable amount of money for his services at a rate agreed
to between the Company and the Participant; and provided further that after the Participant’s termination of employment with the Company such assistance shall
not unreasonably interfere with the Participant’s business or personal obligations. The Participant agrees to promptly inform the Company if the Participant
becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or its affiliates. The Participant also agrees to promptly
inform the Company (to the extent the Participant is legally permitted to do so) if the Participant is asked to assist in any investigation of the Company or its
affiliates (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or its affiliates with respect to such
investigation, and shall not do so unless legally required. Provided, however, the Participant is not required to inform the Company of any investigation by a
governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and
the Participant may participate in such investigation, without informing the Company.
12. 	No Right to Continued Employment. Neither the Option nor any terms contained in this Agreement shall confer upon the Participant
any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any way the right of the
Company, which right is hereby expressly reserved, to terminate the Participant’s employment or service at any time with or without Cause. The Participant
acknowledges and agrees that any right to exercise the Option is earned only by continuing as an employee of the Company or an Affiliate at the will of the
Company or such Affiliate, or satisfaction of any other applicable terms and conditions contained in the Plan and this Agreement, and not through the act of being
hired, being granted the Option or acquiring Shares hereunder.

-- 73 of 97 --

13. 	The Plan. This Agreement is subject to all the terms, provisions and conditions of the Plan, which are incorporated herein by
reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the
event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be
modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus
shall be provided to the Participant upon the Participant’s written request to the Company at Anthem, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204,
Attention: Corporate Secretary, Shareholder Services Department.
14. 	Compliance with Laws and Regulations.
(a) 	The Option and the obligation of the Company to sell and deliver Shares hereunder shall be subject in all respects to (i) all applicable
Federal and state laws, rules and regulations and (ii) any registration, qualification, approvals or other requirements imposed by any government or regulatory
agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Option may not be exercised if its exercise, or
the receipt of Shares pursuant thereto, would be contrary to applicable law. If at any time the Company determines, in its discretion, that the listing, registration or
qualification of Shares upon any national securities exchange or under any state or Federal law, or the consent or approval of any governmental regulatory body, is
necessary or desirable, the Company shall not be required to deliver any certificates for Shares to the Participant or any other person pursuant to this Agreement
unless and until such listing, registration, qualification, consent or approval has been effected or obtained, or otherwise provided for, free of any conditions not
acceptable to the Company.
(b) 	The Shares received upon the exercise of the Option shall have been registered under the Securities Act of 1933 (“Securities Act”).
If the Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act (“Rule 144”), the Participant may not sell the Shares
received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the Company may bear a legend setting forth such
restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal and state securities laws.
(c) 	If at the time of exercise of all or part of the Option, the Shares are not registered under the Securities Act, and/or there is no current
prospectus in effect under the Securities Act with respect to the Shares, the Participant shall execute, prior to the delivery of any Shares to the Participant by the
Company pursuant to this Agreement, an agreement (in such form as the Company may specify) in which the Participant represents and warrants that the
Participant is purchasing or acquiring the shares acquired under this Agreement for the Participant's own account, for investment only and not with a view to the
resale or distribution thereof, and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to
either (i) a registration statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to
the Shares being offered or sold, or (ii) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption the
Participant shall, prior to any offer for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from
counsel for or approved by the Company, as to the applicability of such exemption thereto.
15. 	Notices. All notices by the Participant or the Participant’s assignees shall be addressed to Anthem, Inc., 220 Virginia Avenue,
Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to the Participant
shall be addressed to the Participant at the Participant’s address in the Company's records.
16. 	Other Plans. The Participant acknowledges that any income derived from the exercise of the Option shall not affect the Participant’s
participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.

-- 74 of 97 --

17. 	Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be
amended from time to time, shall apply to the Option, any Shares acquired upon exercise of the Option and any profits realized from the sale of such Shares to the
extent that the Participant is covered by such policy. If the Participant is covered by such policy, the policy may apply to recoup the Option, any Shares acquired
upon exercise of the Option or profits realized from the sale of Shares previously covered by the Option either before, on or after the date on which the Participant
becomes subject to such policy.
ANTHEM, INC.
By: 	______________________________
Printed: 	Lewis Hay III
Its: 	Chair, Compensation Committee of the Board of Directors

-- 75 of 97 --

EXHIBIT 10.2(m)
Schedule A
Notice of Restricted Stock Unit Grant
Participant: 	[•]
Company: 	Anthem, Inc.
Notice: 	You have been granted the following award of restricted stock units of common stock of the Company in
accordance with the terms of the Plan and the attached Restricted Stock Unit Award Agreement.
Plan: 	2017 Anthem Incentive Compensation Plan
Grant: 	Grant Date[•]
Number of Restricted Stock Units: [•]
Period of Restriction: 	The Period of Restriction applicable to the number of your Restricted Stock Units listed in the “Shares” column
below, and any related Dividend Equivalents, shall commence on the Grant Date and shall lapse on the date listed
in the “Lapse Date” column below.
Shares 	Lapse Date
[•] 	[•]
[•] 	[•]
[•] 	[•]
In the event that a Change of Control (as defined in the Plan) occurs before your Termination, your Restricted
Stock Unit Grant will remain subject to the terms of this Agreement, unless the successor company does not
assume the Restricted Stock Unit Grant. If the successor company does not assume the Restricted Stock Unit
Grant, then the Period of Restriction shall immediately lapse upon a Change of Control and the Shares covered by
the award shall be immediately delivered upon the Change of Control, provided that in the event that the
Restricted Stock Unit Grant is deferred compensation within the meaning of Code Section 409A, such Shares shall
only be delivered upon the Change of Control if such Change of Control is a “change in control event” within the
meaning of Code Section 409A and the delivery is made in accordance with Treasury Regulation 1-409A-3(j)(ix).
Acceptance: 	In order to accept your Restricted Stock Units, you must electronically accept this Agreement through the
Company’s broker at any time within ninety (90) days after the Grant Date. To effect your acceptance, please
follow the instructions included with your grant materials. Acceptance of the Agreement includes acceptance of
the terms and conditions of the Plan. If you do not timely and electronically accept this Agreement, this Agreement
will be null and void as of the 90th day after the Grant Date and you will have no right or claim to the Restricted
Stock Units described above.

-- 76 of 97 --

Restricted Stock Unit Award Agreement
This Restricted Stock Unit Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of
Restricted Stock Unit Grant attached as Schedule A hereto (the “Grant Notice”) is made between Anthem, Inc. (the “Company”) and the Participant set forth in the
Grant Notice. The Grant Notice is included in and made part of this Agreement.
1. 	Period of Restriction. The Period of Restriction with respect to the Restricted Stock Units shall be as set forth in the Grant Notice (the
“Period of Restriction”). The Participant acknowledges that prior to the expiration of the applicable portion of the Period of Restriction, the Restricted Stock Units
may not be sold, transferred, pledged, assigned, encumbered, alienated, hypothecated or otherwise disposed of (whether voluntary or involuntary or by operation of
law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy)). Upon the expiration of the applicable portion
of the Period of Restriction described in the attached Grant Notice, the restrictions set forth in this Agreement with respect to the Restricted Stock Units theretofore
subject to such expired Period of Restriction shall lapse and the Shares covered by the related portion of the award shall be immediately delivered, except as may
be provided in accordance with Sections 8 and 15 hereof.
2. 	Ownership. Upon expiration of the applicable portion of the Period of Restriction described in the attached Grant Notice, the
Company shall transfer the Shares covered by the related portion of the award to the Participant’s account with the Company’s captive broker.
3. 	Termination.
(a) 	Retirement. 	If the Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as the
Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service or after attaining age sixty-five (65)), the restrictions
upon the Restricted Stock Units shall continue to lapse throughout the Period of Restriction and the Shares covered by the related portion of the Restricted Stock
Units shall continue to be delivered upon the applicable Lapse Date; 	provided, however, 	that if the Participant’s Termination due to Retirement is during the
calendar year of the Grant Date, the Restricted Stock Units shall be forfeited on a pro-rata basis, measured by the number of completed full months in that calendar
year during which the Participant was employed by the Company or an Affiliate (e.g., if the Participant’s Retirement occurs in September, 33.3% (or 4/12) of the
Restricted Stock Units will be forfeited), and the Period of Restriction on the non-forfeited portion of the Restricted Stock Units shall continue to lapse throughout
the Period of Restriction described in the attached Grant Notice and the Shares covered by the related portion of the Restricted Stock Units shall continue to be
delivered upon the applicable Lapse Date. 	1
(b) 	Death and Disability. If the Participant’s Termination is due to death or Disability (for purposes of this Agreement, as
defined in the applicable Anthem Long-Term Disability Plan), then the Period of Restriction shall immediately lapse, causing any restrictions which would
otherwise remain on the Restricted Stock Units to immediately lapse and the Shares covered by the Restricted Stock Units shall be immediately delivered.
(c) 	Without Cause. 	Unless 3(a) is applicable, if the Participant’s Termination is by the Company or an Affiliate without Cause
(for purposes of this Agreement, defined as a violation of “conduct” as such term is defined in the Anthem HR Corrective Action Policy and if the Participant
participates in the Anthem, Inc. Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement or the Key Sales Associate Agreement also as
defined in that plan or agreement) and the Participant is receiving severance under the Agreement Plan, the Anthem Supplemental Unemployment Benefit Plan, the
Anthem Excess Termination Benefit Plan, the Key Associate Agreement or the Key Sales Associate Agreement and any portion of the Period of Restriction has
not lapsed as of the Participant’s Termination, the Period of Restriction shall continue to lapse through the earlier of (A) the last day of the period for which the
Participant is receiving severance or (B) the last Lapse Date in the schedule set forth in the Grant Notice.
(d) 	Other Terminations. If the Participant’s Termination is (i) by the Company or an Affiliate for Cause even if on the date of
such Termination the Participant has met the definition of Retirement or Disability or (ii) by the Participant for any reason other than death, Disability or
Retirement, then all Restricted Stock
1 	This retirement provision is deleted in non-annual retention grants.

-- 77 of 97 --

Units for which the Period of Restriction had not lapsed prior to the date of such Termination shall be immediately forfeited.
(e) 	Termination after Change of Control. 	Notwithstanding any other provision of the Agreement, including Section 3(c), if
after a Change of Control the Participant’s Termination is (i) by the Company or an Affiliate without Cause (for purposes of this Agreement, defined as a violation
of “conduct” as such term is defined in the Anthem HR Corrective Action Policy and if the Participant participates in the Agreement Plan, the Key Associate
Agreement or the Key Sales Associate Agreement also as defined in that plan or agreement) or (ii) if the Participant participates in the Agreement Plan, by the
Participant for Good Reason (as defined in the Agreement Plan), then the Period of Restriction on all Restricted Stock Units shall immediately lapse, causing any
restrictions which would otherwise remain on the Restricted Stock Units to immediately lapse and the Shares covered by the Restricted Stock Units shall be
immediately delivered. Notwithstanding any provision of this Agreement to the contrary, in the event that the restrictions on any Restricted Stock Units lapse under
any provision of this Section 3 by reason of any Termination and such Termination occurs within the two year period following a Change of Control that is a
“change in control event” within the meaning of Code Section 409A, the Shares subject to the Participant’s Restricted Stock Units shall be delivered to the
Participant immediately upon such Termination.
4. 	Transferability of the Restricted Stock Units. The Participant shall have the right to appoint any individual or legal entity in writing,
on a Designation of Beneficiary form, as his/her beneficiary to receive any Restricted Stock Units (to the extent not previously terminated or forfeited) under this
Agreement upon the Participant’s death. Such designation under this Agreement may be revoked by the Participant at any time and a new beneficiary may be
appointed by the Participant by execution and submission to the Company, or its designee, of a revised Designation of Beneficiary form to this Agreement. In order
to be effective, a designation of beneficiary must be completed by the Participant on the Designation of Beneficiary form and received by the Company, or its
designee, prior to the date of the Participant’s death. If the Participant dies without such designation, the Restricted Stock Units will become part of the
Participant’s estate.
5. 	Dividend Equivalents. In the event the Company declares a dividend on Shares (as defined in the Plan), for each unvested Restricted
Stock Unit on the dividend payment date, the Participant shall be credited with a Dividend Equivalent, payable in cash, with a value equal to the value of the
declared dividend. The Dividend Equivalents shall be subject to the same restrictions as the unvested Restricted Stock Units to which they relate. No interest or
other earnings shall be credited on the Dividend Equivalents. Subject to continued employment with the Company and Affiliates, the restrictions with respect to the
Dividend Equivalents shall lapse at the same time and in the same proportion as the initial award of Restricted Stock Units. No additional Dividend Equivalents
shall be accrued for the benefit of the Participant with respect to record dates occurring prior to, or with respect to record dates occurring on or after the date, if
any, on which the Participant has forfeited the Restricted Stock Units or any Restricted Stock Units have been settled. For any specified employee, any Dividend
Equivalents subject to Code Section 409A and payable upon a termination of employment shall be subject to a six month delay. The Dividend Equivalents shall be
subject to all such other provisions set forth herein, and may be used to satisfy any or all obligations for the payment of any tax attributable to the Dividend
Equivalents and/or Restricted Stock Units.
6. 	Taxes and Withholdings. Upon the expiration of the applicable portion of the Period of Restriction (and delivery of the underlying
Shares), or as of which the value of any Restricted Stock Units first becomes includible in the Participant’s gross income for income tax purposes, the Participant
shall satisfy all obligations for the payment of any tax attributable to the Restricted Stock Units. The Participant shall notify the Company if the Participant wishes
to pay the Company in cash, check or with shares of Anthem common stock already owned for the satisfaction of any taxes of any kind required by law to be
withheld with respect to such Restricted Stock Units. Any such election made by the Participant must be irrevocable, made in writing, signed by the Participant,
and shall be subject to any restrictions or limitations that the Compensation Committee of the Board of Directors of the Company (“Committee”), in its sole
discretion, deems appropriate. If the Participant does not notify the Company in writing at least 14 days prior to the applicable lapse of the Period of Restriction,
the Committee is authorized to take any such other action as may be necessary or appropriate, as determined by the Committee, to satisfy all obligations for the
payment of such taxes. Such other actions may include withholding the required amounts from other compensation payable to the Participant, a sell-to-cover
transaction or such other method determined by the Committee, in its discretion.
7. 	Restrictive Covenants. For purposes of Section 7, 8, 9, 10 and 11 of this Agreement, Company shall mean Anthem, Inc. and its
subsidiaries and affiliates. The Participant acknowledges that s/he has the right to consult with counsel at the Participant’s sole expense. As a condition to receipt of
the Restricted Stock Unit Grant made under this Agreement and/or award of vested Restricted Stock Units, which the Participant and the Company agree is fair and
reasonable consideration, the Participant agrees as follows:

-- 78 of 97 --

(a) 	Confidentiality.
(i) 	The Participant recognizes that the Company derives substantial economic value from information created and
used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs,
formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the
Company, its affiliates and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the
Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists);
manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance
and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential
concepts and ideas related to the Company’s business (collectively, “Confidential Information”). The Participant expressly acknowledges and
agrees that by virtue of his/her employment with the Company, the Participant will have access and will use in the course of the Participant’s
duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business
information of the Company, all of which is the exclusive property of the Company. For purposes of this Agreement, Confidential Information
includes the foregoing and other information protected under the Indiana Uniform Trade Secrets Act (the “Act”), or to any comparable
protection afforded by applicable law, but does not include information that the Participant establishes by clear and convincing evidence is or
may become known to the Participant or to the public from sources outside the Company and through means other than a breach of this
Agreement. Notwithstanding the foregoing, in accordance with the Defend Trade Secrets Act of 2016, the Participant will not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence to a federal,
state, or local government official, either directly or indirectly, or to an attorney; and (2) solely for the purpose of reporting or investigating a
suspected violation of law; or (B) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If the
Participant files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Participant may disclose the Company’s
trade secrets to his/her attorney and use the trade secret information in the court proceeding if the Participant (A) files any document containing
the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.
(ii) 	The Participant agrees that the Participant will not for himself or herself or for any other person or entity, directly
or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential
Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce
any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform the Participant’s
duties for the Company or its affiliates; or (C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to
any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal
device or media. Upon termination of employment, the Participant shall return all Confidential Information and all other property of the
Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains
Confidential Information. Provided, however, nothing in this Agreement prohibits or limits the Participant from (i) reporting possible violations
of federal securities law or regulation to any governmental agency or entity or (ii) receiving a monetary award from the governmental agency or
entity for the information reported.
(b) 	Non-Competition. 	During any period in which the Participant is employed by the Company, and during a period of time
after the Participant’s termination of employment (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months
for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other
Participants, the Participant will not, without prior written consent of the Company, directly or indirectly seek or obtain a Competitive Position in a Restricted
Territory and perform a Restricted Activity with a Competitor, as those terms are defined herein.

-- 79 of 97 --

(i) 	Competitive Position means any employment or performance of services with a Competitor (A) the same as or
similar to the services in which Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with
Company, or (B) in which the Participant will use any Confidential Information of the Company.
(ii) 	Restricted Territory means any geographic area in which the Company does business and in which the Participant
provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such
business, within the thirty-six (36) months prior to the Participant’s termination of employment from the Company.
(iii) 	Restricted Activity means any activity for which the Participant had responsibility for the Company within the
thirty-six (36) months prior to the termination of the Participant’s employment from the Company or about which the Participant had
Confidential Information.
(iv) 	Competitor means any entity or individual (other than the Company or its affiliates) engaged in management of
network-based managed care plans and programs, or the performance of managed care services, health insurance, long term care insurance,
dental, life or disability insurance, behavioral health, vision, flexible spending accounts and COBRA administration or other products or services
substantially the same or similar to those offered by the Company while the Participant was employed, or other products or services offered by
the Company within twelve (12) months after the termination of Participant’s employment if the Participant had responsibility for, or
Confidential Information about, such other products or services while the Participant was employed by the Company.
(v) 	The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position
that consists of practicing law.
(c) 	Non-Solicitation of Customers. 	During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, consultant,
independent contractor, owner, agent, or in any other capacity, directly or indirectly, for a Competitor of the Company as defined in subsection (b) above: (i) solicit
business from any client or account of the Company or any of its affiliates with which the Participant had contact, participated in the contact, or responsibility for,
or about which the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, (ii) solicit business from
any client or account which was pursued by the Company or any of its affiliates and with which the Participant had contact, or responsibility for, or about which
the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, within the twelve (12) month period prior
to termination of employment. For purposes of this provision, an individual policyholder in a plan maintained by the Company or by a client or account of the
Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or
account subject to this restriction solely by reason of being such a policyholder or certificate holder.
(d) 	Non-Solicitation of Employees. 	During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, independent
contractor, owner, agent, or in any other capacity, directly or indirectly solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any
non-Company affiliated entity, any person who on or during the six (6) months immediately preceding the date of such solicitation or hire is or was an officer or
employee of the Company, or whom the Participant was involved in recruiting while the Participant was employed by the Company.
(e) 	Non-Disparagement. 	The Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make
any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business
reputation of the Company’s directors, employees, officers and managers. Further, the Participant will not at any time make any verbal or written statement to any
media outlet regarding the Company.

-- 80 of 97 --

8. 	Return of Consideration.
(a) 	If at any time a Participant breaches any provision of Section 7 or Section 11 then: (i) all unexercised Company stock
options under any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate; (ii) the
Participant shall forfeit any outstanding restricted stock or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of
breach; and (iii) the Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an
option under a Designated Plan within the 24 months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the
exercise price, and (B) for each share of restricted stock and/or performance stock that became vested under any Designated Plan within the 24 months prior to
such breach, the fair market value (on the date of vesting) of a Common Share. Any amount to be repaid pursuant to this Section 8 shall be held by the Participant
in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by the Participant to
the Company with interest from the date such Common Share was acquired or the share of restricted stock became vested, as the case may be, to the date of
payment, at 120% of the applicable six month short-term applicable federal rate. Any amount described in clauses (i) and (ii) that the Participant forfeits as a result
of a breach of the provisions of Sections 7 or 11 shall not reduce any money damages that would be payable to the Company as compensation for such breach.
(b) 	The amount to be repaid pursuant to this Section 8 shall be determined on a gross basis, without reduction for any taxes
incurred, as of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have
the right to offset such amount against any amounts otherwise owed to the Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit
plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c) 	For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or
long-term incentive compensation plan.
9. 	Equitable Relief and Other Remedies. As a condition to this Agreement:
(a) 	The Participant acknowledges that each of the provisions of Section 7 and 8 of the Plan are reasonable and necessary to
preserve the legitimate business interests of the Company, its present and potential business activities and the economic benefits derived therefrom; that they will
not prevent him or her from earning a livelihood in the Participant’s chosen business and are not an undue restraint on the trade of the Participant, or any of the
public interests which may be involved.
(b) 	The Participant agrees that beyond the amounts otherwise to be provided under the Plan and this Agreement, the Company
will be damaged by a violation of the terms of this Agreement and the amount of such damage may be difficult to measure. The Participant agrees that if the
Participant commits or threatens to commit a breach of any of the covenants and agreements contained in Sections 7 or 11 to the extent permitted by applicable
law, then the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as
required by law, in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such
breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Further, if the Participant violates Section
7 hereof the Participant agrees that the period of violation shall be added to the period in which the Participant’s activities are restricted.
(c) 	Notwithstanding the foregoing, the Company will not seek injunctive relief to prevent a Participant residing in California
from engaging in post termination competition in California under Section 7(b) or (c) of this Agreement, provided that the Company may seek and obtain relief to
enforce Section 8 of this Agreement with respect to such Participants.
(d) 	The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration,
scope, area or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the parties agree that the
maximum duration, scope, area or activity restrictions reasonable and enforceable under such circumstances shall be substituted for the stated duration, scope, area
or activity restrictions to the maximum extent permitted by law. The parties further agree that the Company’s rights under Section 8 should be enforced to the
fullest extent permitted by law irrespective of whether the Company seeks equitable relief in addition to relief provided therein or if the arbitrator or court deems
equitable relief to be inappropriate.

-- 81 of 97 --

10. 	Survival of Provisions. The obligations contained in Sections 7, 8, 9 and Section 11 shall survive the Termination of the
Participant’s employment with the Company and shall be fully enforceable thereafter.
11. 	Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), the
Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after
the termination of Participant’s employment for any reason, the Participant will respond and provide information with regard to matters in which the Participant
has knowledge as a result of the Participant’s employment with the Company, and will provide reasonable assistance to the Company, its affiliates and their
respective representatives in defense of any claims that may be made against the Company or its affiliates, and will assist the Company and its affiliates in the
prosecution of any claims that may be made by the Company or its affiliates, to the extent that such claims may relate to the period of the Participant’s employment
with the Company (or any predecessor); provided, that with respect to periods after the termination of the Participant’s employment, the Company shall reimburse
the Participant for any out-of-pocket expenses incurred in providing such assistance and if the Participant is required to provide more than ten (10) hours of
assistance per week after his termination of employment then the Company shall pay the Participant a reasonable amount of money for his services at a rate agreed
to between the Company and the Participant; and provided further that after the Participant’s termination of employment with the Company such assistance shall
not unreasonably interfere with the Participant’s business or personal obligations. The Participant agrees to promptly inform the Company if the Participant
becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or its affiliates. The Participant also agrees to promptly
inform the Company (to the extent the Participant is legally permitted to do so) if the Participant is asked to assist in any investigation of the Company or its
affiliates (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or its affiliates with respect to such
investigation, and shall not do so unless legally required. Provided, however, the Participant is not required to inform the Company of any investigation by a
governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and
the Participant may participate in such investigation, without informing the Company.
12. 	No Rights as a Shareholder. The Participant shall have no rights of a shareholder (including, without limitation, dividend and voting
rights) with respect to the Restricted Stock Units, for record dates occurring on or after the Grant Date and prior to the date any such Restricted Stock Units vest in
accordance with this Agreement.
13. 	No Right to Continued Employment. Neither the Restricted Stock Units nor any terms contained in this Agreement shall confer
upon the Participant any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any
way the right of the Company, which right is hereby expressly reserved, to terminate the Participant’s employment or service at any time for any reason. The
Participant acknowledges and agrees that any right to have restrictions on the Restricted Stock Units lapse is earned only by continuing as an employee of the
Company or an Affiliate at the will of the Company or such Affiliate, or satisfaction of any other applicable terms and conditions contained in the Plan and this
Agreement, and not through the act of being hired, being granted the Restricted Stock Units or acquiring Shares hereunder.
14. 	The Plan. This Agreement is subject to all the terms, provisions and conditions of the Plan, which are incorporated herein by
reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the
event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be
modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus
shall be provided to the Participant upon the Participant’s written request to the Company at Anthem, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204,
Attention: Corporate Secretary, Shareholder Services Department.

-- 82 of 97 --

15. 	Compliance with Laws and Regulations.
(a) 	The Restricted Stock Units and the obligation of the Company to deliver Shares hereunder shall be subject in all respects to
(i) all applicable Federal and state laws, rules and regulations and (ii) any registration, qualification, approvals or other requirements imposed by any government
or regulatory agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Company shall not deliver any
certificates for Shares to the Participant or any other person pursuant to this Agreement if doing so would be contrary to applicable law. If at any time the Company
determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal law, or the
consent or approval of any governmental regulatory body, is necessary or desirable, the Company shall not be required to deliver any certificates for Shares to the
Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification, consent or approval has been effected or
obtained, or otherwise provided for, free of any conditions not acceptable to the Company.
(b) 	The Shares received upon the expiration of the applicable portion of the Period of Restriction shall have been registered
under the Securities Act of 1933 (“Securities Act”). If the Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act
(“Rule 144”), the Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the
Company may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal
and state securities laws.
(c) 	If, at any time, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under
the Securities Act with respect to the Shares, the Participant shall execute, prior to the delivery of any Shares to the Participant by the Company pursuant to this
Agreement, an agreement (in such form as the Company may specify) in which the Participant represents and warrants that the Participant is purchasing or
acquiring the shares acquired under this Agreement for the Participant’s own account, for investment only and not with a view to the resale or distribution thereof,
and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration
statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered
or sold, or (ii) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption the Participant shall, prior to any offer
for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from counsel for or approved by the Company,
as to the applicability of such exemption thereto.
16. 	Code Section 409A Compliance. Except with respect to Participants who are Retirement eligible or become Retirement eligible
before the calendar year containing the second Lapse Date as shown on the Grant Notice, it is intended that this Agreement meet the short-term deferral exception
from Code Section 409A. This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the
Agreement or Plan to fail to satisfy this exception shall have no force and effect. Notwithstanding anything contained herein to the contrary, Shares in respect of
any Restricted Stock Units that (a) constitute “nonqualified deferred compensation” as defined under Code Section 409A and (b) vest as a consequence of the
Participant’s Termination shall not be delivered until the date that the Participant incurs a “separation from service” within the meaning of Code Section 409A (or,
if the Participant is a “specified employee” within the meaning of Code Section 409A and the regulations promulgated thereunder, the date that is six months
following the date of such “separation from service” (or death, if earlier)). In addition, each amount to be paid or benefit to be provided to the Participant pursuant
to this Agreement that constitutes deferred compensation subject to Code Section 409A, shall be construed as a separate identified payment for purposes of Code
Section 409A.
17. 	Notices. All notices by the Participant or the Participant’s assignees shall be addressed to Anthem, Inc., 220 Virginia Avenue,
Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to the Participant
shall be addressed to the Participant at the Participant’s address in the Company’s records.
18. 	Other Plans. The Participant acknowledges that any income derived from the Restricted Stock Units shall not affect the Participant’s
participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.

-- 83 of 97 --

19. 	Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be
amended from time to time, shall apply to the Restricted Stock Units, any Shares delivered hereunder and any profits realized on the sale of such Shares to the
extent that the Participant is covered by such policy. If the Participant is covered by such policy, the policy may apply to recoup Restricted Stock Units awarded,
any Shares delivered hereunder or profits realized on the sale of such Shares either before, on or after the date on which the Participant becomes subject to such
policy.
ANTHEM, INC.
By:
Printed: Lewis Hay III
Its: Chair, Compensation Committee
of the Board of Directors

-- 84 of 97 --

EXHIBIT 10.2(n)
Schedule A
Notice of Performance Stock Unit Grant
Participant: 	[•]
Company: 	Anthem, Inc.
Notice: 	You have been granted the following award of performance stock units of common stock of the Company in
accordance with the terms of the Plan and the attached Performance Stock Unit Agreement.
Plan: 	2017 Anthem Incentive Compensation Plan
Grant: 	Grant Date: [•]
Number of Performance Stock Units: [•]
Performance Period: 	The Performance Period is the three calendar year period that begins on the January 1 of the calendar year that
includes the Grant Date. Subject to achievement of the performance measures described in the Long Term Stock
Incentive Plan Brochure (“Summary”), the number of your Performance Stock Units listed in the “Shares”
column, and any related Dividend Equivalents shall vest on the later of the date listed in the “Vesting Date”
column or the date the Compensation Committee of the Board of Directors of Anthem, Inc. certifies the
performance results. Unless otherwise provided in the Agreement, you must be employed on the Vesting Date to
receive any Performance Stock Units payable under the Agreement. Achievement of the performance measures
may increase or decrease the total number of Performance Stock Units covered by the Grant and any related
Dividend Equivalents that vest on the Vesting Date.
Shares 	Vesting Date
[•] 	[•]
Achievement of the performance measures must be approved by the Compensation Committee of the Board of
Directors of Anthem, Inc. The performance measures as described in the Summary, including any modifications to
such performance measures, are incorporated into and made part of the Agreement.
In the event that a Change of Control (as defined in the Plan) occurs before your Termination, your Performance
Stock Unit Grant will remain subject to the terms of this Agreement, unless the successor company does not
assume the Performance Stock Unit Grant. If the successor company does not assume the Performance Stock Unit
Grant, then the Performance Stock Units shall immediately vest upon a Change of Control and the Shares covered
by the award shall be immediately delivered upon the Change of Control, provided that in the event that the
Performance Stock Units are deferred compensation within the meaning of Code Section 409A, such Stock Units
shall only be delivered upon the Change of Control if such Change of Control is a “change in control event” within
the meaning of Code Section 409A and the delivery is made in accordance with Treasury Regulation 1-409A-3(j)
(ix).
Acceptance: 	In order to accept your Performance Stock Units, you must electronically accept this Agreement through the
Company’s broker at any time within ninety (90) days after the Grant Date. To effect your acceptance, please
follow the instructions included with your grant materials. Acceptance of the Agreement includes acceptance of
the terms and conditions of the Plan. If you do not timely and electronically accept this Agreement, this Agreement
will be null and void as of the 90th day after the Grant Date and you will have no right or claim to the Performance
Stock Units described above.

-- 85 of 97 --

EXHIBIT 10.2(n)
Performance Stock Unit Award Agreement
This Performance Stock Unit Award Agreement (this “Agreement”) dated as of the Grant Date (the “Grant Date”) set forth in the Notice of
Performance Stock Unit Grant attached as Schedule A hereto (the “Grant Notice”) is made between Anthem, Inc. (the “Company”) and the Participant set forth in
the Grant Notice. The Grant Notice is included in and made part of this Agreement.
1. 	Performance Period. The Performance Period with respect to the Performance Stock Units shall be as set forth in the Grant Notice
(the “Performance Period”). The Participant acknowledges that the Performance Stock Units may not be sold, transferred, pledged, assigned, encumbered,
alienated, hypothecated or otherwise disposed of (whether voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other
legal or equitable proceedings (including bankruptcy)). Upon the completion of the applicable portion of the Performance Period and subject to the performance
measures described in the Summary, the restrictions set forth in this Agreement with respect to the Performance Stock Units theretofore subject to such completed
Performance Period shall lapse and the Shares covered by the related portion of the award shall be immediately delivered, except as may be provided in accordance
with Sections 8 and 15 hereof.
2. 	Ownership. Upon expiration of the applicable portion of the Performance Period and subject to the performance measure described in
the Summary, the Company shall transfer the Shares covered by the related portion of the award to the Participant’s account with the Company’s captive broker.
3. 	Termination.
(a) 	Retirement. 	If the Participant’s Termination is due to Retirement (for purposes of this Agreement, defined as the
Participant’s Termination after attaining age fifty-five (55) with at least ten (10) completed years of service) or after attaining age sixty-five (65), the Participant
shall become vested in a prorata number of Performance Stock Units based on actual achievement of the performance measures set forth in the Summary. For
purposes of the preceding, the prorata number of the Performance Stock Units shall be equal to (i) the number of Performance Stock Units set forth in the Grant
Notice, adjusted for actual achievement of performance measures, plus any Dividend Equivalents multiplied by (ii) a fraction, the numerator of which shall be the
number of full calendar months the Participant is employed with the Company during the Measurement Period and the denominator of which shall be 36 calendar
months. For purposes of the Agreement, the Measurement Period is (A) the same as the Performance Period for a Participant employed on the first day of the
Performance Period, and (B) the 36 month period beginning on the Grant Date for all other Participants. The shares covered by the related portion of the award
shall be delivered upon the applicable Vesting Date. 	1
(b) 	Death and Disability. If the Participant’s Termination is due to death or Disability (for purposes of this Agreement, as
defined in the applicable Anthem Long-Term Disability Plan), then the Performance Period shall immediately lapse, causing any restrictions which would
otherwise remain on the Performance Stock Units to immediately lapse, and the Shares covered by the award shall be immediately delivered.
(c) 	Without Cause. If the Participant’s Termination is by the Company or an Affiliate without Cause (for purposes of this
Agreement, defined as a violation of “conduct” as such term is defined in the Anthem HR Corrective Action Policy and if the Participant participates in the
Anthem, Inc. Executive Agreement Plan (the "Agreement Plan"), the Key Associate Agreement, or the Key Sales Associate Agreement also as defined in that plan
or agreement), the Participant shall become vested in a prorata number of Performance Stock Units based on actual achievement of the performance measures set
forth in the Summary. For purposes of the preceding, the prorata number of the Performance Stock Units shall be equal to (i) the number of Performance Stock
Units set forth in the Grant Notice, adjusted for actual achievement of performance measures, plus any Dividend Equivalents multiplied by (ii) a fraction, the
numerator of which shall be the number of full calendar months elapsed from the first day of the Measurement Period through the Participant’s date of Termination
and the denominator of which shall be 36 calendar months. The shares covered by the related portion of the award shall be delivered upon the applicable Vesting
Date.
(d) 	Other Terminations. If the Participant’s Termination is (i) by the Company or an Affiliate for Cause even if on the date of
such Termination the Participant has met the definition of Retirement or Disability or (ii) by the Participant for any reason other than death, Disability, Retirement
or without Cause, then all Performance Stock Units for which the Performance Period had not lapsed prior to the date of such Termination shall be immediately
forfeited.
1This retirement provision is deleted in non-annual retention grants.

-- 86 of 97 --

EXHIBIT 10.2(n)
(e) 	Termination after Change of Control. 	If after a Change of Control the Participant’s Termination is (i) by the Company or an
Affiliate without Cause or (ii), if the Participant participates in the Agreement Plan, by the Participant for Good Reason (as defined in the Agreement Plan), then
there shall be paid out in cash to the Participant within 30 days following termination of employment the value of the Performance Stock Units to which the
Participant would have been entitled if performance achieved 100% of the target performance measures as described in the Summary. Notwithstanding any
provision of this Agreement to the contrary, in the event that the Participant becomes entitled to vest in Performance Stock Units under any provision of this
Section 3 by reason of any Termination and such Termination occurs within the two year period following a Change of Control that is a “change in control event”
within the meaning of Code Section 409A, the Participant’s Performance Stock Units shall be paid to the Participant immediately upon such Termination.
4. 	Transferability of the Performance Stock Units. The Participant shall have the right to appoint any individual or legal entity in
writing, on a Designation of Beneficiary form, as his/her beneficiary to receive any Shares (to the extent not previously terminated or forfeited) under this
Agreement upon the Participant’s death. Such designation under this Agreement may be revoked by the Participant at any time and a new beneficiary may be
appointed by the Participant by execution and submission to the Company, or its designee, of a revised Designation of Beneficiary form to this Agreement. In order
to be effective, a designation of beneficiary must be completed by the Participant on the Designation of Beneficiary form and received by the Company, or its
designee, prior to the date of the Participant’s death. If the Participant dies without such designation, the Performance Stock Units will become part of the
Participant’s estate.
5. 	Dividend Equivalents. In the event the Company declares a dividend on Shares (as defined in the Plan), for each unvested
Performance Stock Unit on the dividend payment date, the Participant shall be credited with a Dividend Equivalent, payable in cash, with a value equal to the value
of the declared dividend. The Dividend Equivalents shall be subject to the same restrictions as the unvested Performance Stock Units to which they relate. No
interest or other earnings shall be credited on the Dividend Equivalents, provided that additional Dividend Equivalents may be awarded or forfeited in the same
proportion as the number of Performance Stock Units determined to be awarded or forfeited based on the achievement of the performance measures. Subject to
continued employment with the Company and Affiliates and, as applicable, achievement of performance measures, the restrictions with respect to the Dividend
Equivalents shall lapse at the same time and in the same proportion as the initial award of Performance Stock Units. No additional Dividend Equivalents shall be
accrued for the benefit of the Participant with respect to record dates occurring prior to, or with respect to record dates occurring on or after the date, if any, on
which the Participant has forfeited the Performance Stock Units or any Performance Stock Units have been settled. For any specified employee, any Dividend
Equivalents subject to Code Section 409A and payable upon a termination of employment shall be subject to a six month delay. The Dividend Equivalents shall be
subject to all such other provisions set forth herein, and may be used to satisfy any or all obligations for the payment of any tax attributable to the Dividend
Equivalents and/or Performance Stock Units.
6. 	Taxes and Withholdings. Upon the expiration of the applicable portion of the Performance Period (and delivery of the underlying
Shares), or as of which the value of any Performance Stock Units first becomes includible in the Participant’s gross income for income tax purposes, the
Participant shall satisfy all obligations for the payment of any tax attributable to the Performance Stock Units. The Participant shall notify the Company if the
Participant wishes to pay the Company in cash, check or with shares of Anthem common stock already owned for the satisfaction of any taxes of any kind required
by law to be withheld with respect to such Performance Stock Units. Any such election made by the Participant must be irrevocable, made in writing, signed by the
Participant, and shall be subject to any restrictions or limitations that the Compensation Committee of the Board of Directors of the Company (“Committee”), in its
sole discretion deems appropriate. If the Participant does not notify the Company in writing at least 14 days prior to the applicable lapse of the Performance Period,
the Committee is authorized to take any such other action as may be necessary or appropriate, as determined by the Committee, to satisfy all obligations for the
payment of such taxes. Such other actions may include withholding the required amounts from other compensation payable to the Participant, a sell-to-cover
transaction or such other method determined by the Committee, in its discretion.

-- 87 of 97 --

EXHIBIT 10.2(n)
7. 	Restrictive Covenants. For purposes of Sections 7, 8, 9, 10 and 11 of this Agreement, Company shall mean Anthem, Inc. and its
subsidiaries and affiliates. The Participant acknowledges that s/he has the right to consult with counsel at the Participant’s sole expense. As a condition to receipt of
the Performance Stock Unit Grant made under this Agreement and/or award of vested Performance Stock Units, which the Participant and the Company agree is
fair and reasonable consideration, the Participant agrees as follows:
(a) 	Confidentiality.
(i) 	The Participant recognizes that the Company derives substantial economic value from information created and
used in its business which is not generally known by the public, including, but not limited to, plans, designs, concepts, computer programs,
formulae, and equations; product fulfillment and supplier information; customer and supplier lists, and confidential business practices of the
Company, its affiliates and any of its customers, vendors, business partners or suppliers; profit margins and the prices and discounts the
Company obtains or has obtained or at which it sells or has sold or plans to sell its products or services (except for public pricing lists);
manufacturing, assembling, labor and sales plans and costs; business and marketing plans, ideas, or strategies; confidential financial performance
and projections; employee compensation; employee staffing and recruiting plans and employee personal information; and other confidential
concepts and ideas related to the Company’s business (collectively, “Confidential Information”). The Participant expressly acknowledges and
agrees that by virtue of his/her employment with the Company, the Participant will have access and will use in the course of the Participant’s
duties certain Confidential Information and that Confidential Information constitutes trade secrets and confidential and proprietary business
information of the Company, all of which is the exclusive property of the Company. For purposes of this Agreement, Confidential Information
includes the foregoing and other information protected under the Indiana Uniform Trade Secrets Act (the “Act”), or to any comparable
protection afforded by applicable law, but does not include information that the Participant establishes by clear and convincing evidence is or
may become known to the Participant or to the public from sources outside the Company and through means other than a breach of this
Agreement. Notwithstanding the foregoing, in accordance with the Defend Trade Secrets Act of 2016, the Participant will not be held criminally
or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A) is made (1) in confidence to a federal,
state, or local government official, either directly or indirectly, or to an attorney; and (2) solely for the purpose of reporting or investigating a
suspected violation of law; or (B) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If the
Participant files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Participant may disclose the Company’s
trade secrets to his/her attorney and use the trade secret information in the court proceeding if the Participant (A) files any document containing
the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.
(ii) 	The Participant agrees that the Participant will not for himself or herself or for any other person or entity, directly
or indirectly, without the prior written consent of the Company, while employed by the Company and thereafter: (A) use Confidential
Information for the benefit of any person or entity other than the Company or its affiliates; (B) remove, copy, duplicate or otherwise reproduce
any document or tangible item embodying or pertaining to any of the Confidential Information, except as required to perform the Participant’s
duties for the Company or its affiliates; or (C) while employed and thereafter, publish, release, disclose or deliver or otherwise make available to
any third party any Confidential Information by any communication, including oral, documentary, electronic or magnetic information transmittal
device or media. Upon termination of employment, the Participant shall return all Confidential Information and all other property of the
Company. This obligation of non-disclosure and non-use of information shall continue to exist for so long as such information remains
Confidential Information. Provided, however, nothing in this Agreement prohibits or limits the Participant from (i) reporting possible violations
of federal securities law or regulation to any governmental agency or entity or (ii) receiving a monetary award from the governmental agency or
entity for the information reported.
(b) 	Non-Competition. 	During any period in which the Participant is employed by the Company, and during a period of time
after the Participant’s termination of employment (the “Restriction Period”) which, unless otherwise limited by applicable state law, is (i) twenty-four (24) months
for Executive Vice Presidents and the President & Chief Executive Officer, and (ii) the greater of the period of severance or twelve (12) months for all other
Participants, the Participant will not, without prior written consent of the Company, directly or indirectly seek or obtain a Competitive Position in a Restricted
Territory and perform a Restricted Activity with a Competitor, as those terms are defined herein.

-- 88 of 97 --

EXHIBIT 10.2(n)
(i) 	Competitive Position means any employment or performance of services with a Competitor (A) the same as or
similar to the services in which Participant performed for the Company in the last twenty-four (24) months of Participant’s employment with
Company, or (B) in which the Participant will use any Confidential Information of the Company.
(ii) 	Restricted Territory means any geographic area in which the Company does business and in which the Participant
provided services in, had responsibility for, had a material presence or influence in, or had access to Confidential Information about, such
business, within the thirty-six (36) months prior to the Participant’s termination of employment from the Company.
(iii) 	Restricted Activity means any activity for which the Participant had responsibility for the Company within the
thirty-six (36) months prior to the termination of the Participant’s employment from the Company or about which the Participant had
Confidential Information.
(iv) 	Competitor means any entity or individual (other than the Company or its affiliates) engaged in management of
network-based managed care plans and programs, or the performance of managed care services, health insurance, long term care insurance,
dental, life or disability insurance, behavioral health, vision, flexible spending accounts and COBRA administration or other products or services
substantially the same or similar to those offered by the Company while the Participant was employed, or other products or services offered by
the Company within twelve (12) months after the termination of Participant’s employment if the Participant had responsibility for, or
Confidential Information about, such other products or services while the Participant was employed by the Company.
(v) 	The restrictions contained in this subsection (b) shall not apply to attorneys who accept a Competitive Position
that consists of practicing law.
(c) 	Non-Solicitation of Customers. 	During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, consultant,
independent contractor, owner, agent, or in any other capacity, directly or indirectly, for a Competitor of the Company as defined in subsection (b) above: (i) solicit
business from any client or account of the Company or any of its affiliates with which the Participant had contact, participated in the contact, or responsibility for,
or about which the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, (ii) solicit business from
any client or account which was pursued by the Company or any of its affiliates and with which the Participant had contact, or responsibility for, or about which
the Participant had knowledge of Confidential Information by reason of the Participant’s employment with the Company, within the twelve (12) month period prior
to termination of employment. For purposes of this provision, an individual policyholder in a plan maintained by the Company or by a client or account of the
Company under which individual policies are issued, or a certificate holder in such plan under which group policies are issued, shall not be considered a client or
account subject to this restriction solely by reason of being such a policyholder or certificate holder.
(d) 	Non-Solicitation of Employees. 	During any period in which the Participant is employed by the Company, and during the
Restriction Period after the Participant’s termination of employment, the Participant will not, either individually or as an employee, partner, independent
contractor, owner, agent, or in any other capacity, directly or indirectly solicit, hire, attempt to solicit or hire, or participate in any attempt to solicit or hire, for any
non-Company affiliated entity, any person who on or during the six (6) months immediately preceding the date of such solicitation or hire is or was an officer or
employee of the Company, or whom the Participant was involved in recruiting while the Participant was employed by the Company.
(e) 	Non-Disparagement. 	The Participant agrees that he/she will not, nor will he/she cause or assist any other person to, make
any statement to a third party or take any action which is intended to or would reasonably have the effect of disparaging or harming the Company or the business
reputation of the Company’s directors, employees, officers and managers. Further, the Participant will not at any time make any verbal or written statement to any
media outlet regarding the Company.

-- 89 of 97 --

EXHIBIT 10.2(n)
8. 	Return of Consideration.
(a) 	If at any time a Participant breaches any provision of Section 7 or Section 11 then: (i) all unexercised Company stock
options under any Designated Plan (defined below) whether or not otherwise vested shall cease to be exercisable and shall immediately terminate; (ii) the
Participant shall forfeit any outstanding restricted stock or other outstanding equity award made under any Designated Plan and not otherwise vested on the date of
breach; and (iii) the Participant shall pay to the Company (A) for each share of common stock of the Company (“Common Share”) acquired on exercise of an
option under a Designated Plan within the 24 months prior to such breach, the excess of the fair market value of a Common Share on the date of exercise over the
exercise price, and (B) for each share of restricted stock and/or performance stock that became vested under any Designated Plan within the 24 months prior to
such breach, the fair market value (on the date of vesting) of a Common Share. Any amount to be repaid pursuant to this Section 8 shall be held by the Participant
in constructive trust for the benefit of the Company and shall, upon written notice from the Company, within 10 days of such notice, be paid by the Participant to
the Company with interest from the date such Common Share was acquired or the share of restricted stock became vested, as the case may be, to the date of
payment, at 120% of the applicable six month short-term applicable federal rate. Any amount described in clauses (i) and (ii) that the Participant forfeits as a result
of a breach of the provisions of Sections 7 or 11 shall not reduce any money damages that would be payable to the Company as compensation for such breach.
(b) 	The amount to be repaid pursuant to this Section 8 shall be determined on a gross basis, without reduction for any taxes
incurred, as of the date of the realization event, and without regard to any subsequent change in the fair market value of a Common Share. The Company shall have
the right to offset such amount against any amounts otherwise owed to the Participant by the Company (whether as wages, vacation pay, or pursuant to any benefit
plan or other compensatory arrangement other than any amount pursuant to any nonqualified deferred compensation plan under Section 409A of the Code).
(c) 	For purposes of this Section 8, a “Designated Plan” is each stock option, restricted stock, or other equity compensation or
long-term incentive compensation plan.
9. 	Equitable Relief and Other Remedies. As a condition to this Agreement:
(a) 	The Participant acknowledges that each of the provisions of Section 7 and 8 of the Plan are reasonable and necessary to
preserve the legitimate business interests of the Company, its present and potential business activities and the economic benefits derived therefrom; that they will
not prevent him or her from earning a livelihood in the Participant’s chosen business and are not an undue restraint on the trade of the Participant, or any of the
public interests which may be involved.
(b) 	The Participant agrees that beyond the amounts otherwise to be provided under the Plan and this Agreement, the Company
will be damaged by a violation of the terms of this Agreement and the amount of such damage may be difficult to measure. The Participant agrees that if the
Participant commits or threatens to commit a breach of any of the covenants and agreements contained in Sections 7 or 11 to the extent permitted by applicable
law, then the Company shall have the right to seek and obtain all appropriate injunctive and other equitable remedies, without posting bond therefor, except as
required by law, in addition to any other rights and remedies that may be available at law or under this Agreement, it being acknowledged and agreed that any such
breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy. Further, if the Participant violates Section
7 hereof the Participant agrees that the period of violation shall be added to the period in which the Participant’s activities are restricted.
(c) 	Notwithstanding the foregoing, the Company will not seek injunctive relief to prevent a Participant residing in California
from engaging in post termination competition in California under Section 7(b) or (c) of this Agreement, provided that the Company may seek and obtain relief to
enforce Section 8 of this Agreement with respect to such Participants.

-- 90 of 97 --

EXHIBIT 10.2(n)
(d) 	The parties agree that the covenants contained herein are severable. If an arbitrator or court shall hold that the duration,
scope, area or activity restrictions stated herein are unreasonable under circumstances then existing, or under applicable state law, the parties agree that the
maximum duration, scope, area or activity restrictions reasonable and enforceable under such circumstances shall be substituted for the stated duration, scope, area
or activity restrictions to the maximum extent permitted by law. The parties further agree that the Company’s rights under Section 8 should be enforced to the
fullest extent permitted by law irrespective of whether the Company seeks equitable relief in addition to relief provided therein or if the arbitrator or court deems
equitable relief to be inappropriate.
10. 	Survival of Provisions. The obligations contained in Sections 7, 8, 9 and Section 11 shall survive the Termination of the
Participant’s employment with the Company and shall be fully enforceable thereafter.
11. 	Cooperation. Upon the receipt of reasonable notice from the Company (including from outside counsel to the Company), the
Participant agrees that while employed by the Company and for two years (or, if longer, for so long as any claim referred to in this Section remains pending) after
the termination of Participant’s employment for any reason, the Participant will respond and provide information with regard to matters in which the Participant
has knowledge as a result of the Participant’s employment with the Company, and will provide reasonable assistance to the Company, its affiliates and their
respective representatives in defense of any claims that may be made against the Company or its affiliates, and will assist the Company and its affiliates in the
prosecution of any claims that may be made by the Company or its affiliates, to the extent that such claims may relate to the period of the Participant’s employment
with the Company (or any predecessor); provided, that with respect to periods after the termination of the Participant’s employment, the Company shall reimburse
the Participant for any out-of-pocket expenses incurred in providing such assistance and if the Participant is required to provide more than ten (10) hours of
assistance per week after his termination of employment then the Company shall pay the Participant a reasonable amount of money for his services at a rate agreed
to between the Company and the Participant; and provided further that after the Participant’s termination of employment with the Company such assistance shall
not unreasonably interfere with the Participant’s business or personal obligations. The Participant agrees to promptly inform the Company if the Participant
becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or its affiliates. The Participant also agrees to promptly
inform the Company (to the extent the Participant is legally permitted to do so) if the Participant is asked to assist in any investigation of the Company or its
affiliates (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or its affiliates with respect to such
investigation, and shall not do so unless legally required. Provided, however, the Participant is not required to inform the Company of any investigation by a
governmental agency or entity resulting from the reporting of possible violations of federal securities law or regulation to any governmental agency or entity, and
the Participant may participate in such investigation, without informing the Company.
12. 	No Rights as a Shareholder. The Participant shall have no rights of a shareholder (including, without limitation, dividend and voting
rights) with respect to the Performance Stock Units, for record dates occurring on or after the Grant Date and prior to the date any such Performance Stock Units
vest in accordance with this Agreement.
13. 	No Right to Continued Employment. Neither the Performance Stock Units nor any terms contained in this Agreement shall confer
upon the Participant any express or implied right to be retained in the employment or service of the Company or any Affiliate for any period, nor restrict in any
way the right of the Company, which right is hereby expressly reserved, to terminate the Participant’s employment or service at any time for any reason. The
Participant acknowledges and agrees that any right to have restrictions on the Performance Stock Units lapse is earned only by continuing as an employee of the
Company or an Affiliate at the will of the Company or such Affiliate, or satisfaction of any other applicable terms and conditions contained in the Plan and this
Agreement, and not through the act of being hired, being granted the Performance Stock Units or acquiring Shares hereunder.
14. 	The Plan. This Agreement is subject to all the terms, provisions and conditions of the Plan, which are incorporated herein by
reference, and to such regulations as may from time to time be adopted by the Committee. Unless defined herein, capitalized terms are as defined in the Plan. In the
event of any conflict between the provisions of the Plan and this Agreement, the provisions of the Plan shall control, and this Agreement shall be deemed to be
modified accordingly. The Plan and the prospectus describing the Plan can be found on the Company’s HR intranet. A paper copy of the Plan and the prospectus
shall be provided to the Participant upon the Participant’s written request to the Company at Anthem, Inc., 220 Virginia Avenue, Indianapolis, Indiana 46204,
Attention: Corporate Secretary, Shareholder Services Department.

-- 91 of 97 --

EXHIBIT 10.2(n)
15. 	Compliance with Laws and Regulations.
(a) 	The Performance Stock Units and the obligation of the Company to deliver Shares hereunder shall be subject in all respects
to (i) all applicable Federal and state laws, rules and regulations and (ii) any registration, qualification, approvals or other requirements imposed by any
government or regulatory agency or body which the Committee shall, in its discretion, determine to be necessary or applicable. Moreover, the Company shall not
deliver any certificates for Shares to the Participant or any other person pursuant to this Agreement if doing so would be contrary to applicable law. If at any time
the Company determines, in its discretion, that the listing, registration or qualification of Shares upon any national securities exchange or under any state or Federal
law, or the consent or approval of any governmental regulatory body, is necessary or desirable, the Company shall not be required to deliver any certificates for
Shares to the Participant or any other person pursuant to this Agreement unless and until such listing, registration, qualification, consent or approval has been
effected or obtained, or otherwise provided for, free of any conditions not acceptable to the Company.
(b) 	The Shares received upon the expiration of the applicable portion of the Performance Period shall have been registered
under the Securities Act of 1933 (“Securities Act”). If the Participant is an “affiliate” of the Company, as that term is defined in Rule 144 under the Securities Act
(“Rule 144”), the Participant may not sell the Shares received except in compliance with Rule 144. Certificates representing Shares issued to an “affiliate” of the
Company may bear a legend setting forth such restrictions on the disposition or transfer of the Shares as the Company deems appropriate to comply with Federal
and state securities laws.
(c) 	If, at any time, the Shares are not registered under the Securities Act, and/or there is no current prospectus in effect under
the Securities Act with respect to the Shares, the Participant shall execute, prior to the delivery of any Shares to the Participant by the Company pursuant to this
Agreement, an agreement (in such form as the Company may specify) in which the Participant represents and warrants that the Participant is purchasing or
acquiring the shares acquired under this Agreement for the Participant’s own account, for investment only and not with a view to the resale or distribution thereof,
and represents and agrees that any subsequent offer for sale or distribution of any kind of such Shares shall be made only pursuant to either (i) a registration
statement on an appropriate form under the Securities Act, which registration statement has become effective and is current with regard to the Shares being offered
or sold, or (ii) a specific exemption from the registration requirements of the Securities Act, but in claiming such exemption the Participant shall, prior to any offer
for sale of such Shares, obtain a prior favorable written opinion, in form and substance satisfactory to the Company, from counsel for or approved by the Company,
as to the applicability of such exemption thereto.
16. 	Code Section 409A Compliance. Except with respect to Participants who are Retirement eligible or become Retirement eligible
before the calendar year containing the Vesting Date as shown on the Grant Notice, it is intended that this Agreement meet the short-term deferral exception from
Code Section 409A. This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement
or Plan to fail to satisfy this exception shall have no force and effect. Notwithstanding anything contained herein to the contrary, Shares in respect of any
Performance Stock Units that (a) constitute “nonqualified deferred compensation” as defined in Code Section 409A and (b) vest as a consequence of the
Participant’s Termination shall not be delivered until the date that the Participant incurs a “separation from service” within the meaning of Code Section 409A (or,
if the Participant is a “specified employee” within the meaning of Code Section 409A and the regulations promulgated thereunder, the date that is six months
following the date of such “separation from service” (or death, if earlier). In addition, each amount to be paid or benefit to be provided to the Participant pursuant
to this Agreement that constitutes deferred compensation subject to Code Section 409A, shall be construed as a separate identified payment for purposes of Code
Section 409A.
17. 	Notices. All notices by the Participant or the Participant’s assignees shall be addressed to Anthem, Inc., 220 Virginia Avenue,
Indianapolis, Indiana 46204, Attention: Stock Administration, or such other address as the Company may from time to time specify. All notices to the Participant
shall be addressed to the Participant at the Participant’s address in the Company’s records.
18. 	Other Plans. The Participant acknowledges that any income derived from the Performance Stock Units shall not affect the
Participant’s participation in, or benefits under, any other benefit plan or other contract or arrangement maintained by the Company or any Affiliate.

-- 92 of 97 --

EXHIBIT 10.2(n)
19. 	Recoupment Policy for Incentive Compensation. The Company's Recoupment Policy for Incentive Compensation, as may be
amended from time to time, shall apply to the Performance Stock Units, any Shares delivered hereunder and any profits realized on the sale of such Shares to the
extent that the Participant is covered by such policy. If the Participant is covered by such policy, the policy may apply to recoup Performance Stock Units awarded,
any Shares delivered hereunder or profits realized on the sale of such Shares either before, on or after the date on which the Participant becomes subject to such
policy.
ANTHEM, INC.
By:
Printed: Lewis Hay III
Its: Chair, Compensation Committee
of the Board of Directors

-- 93 of 97 --

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. 	I have reviewed this report on Form 10-Q of Anthem, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b) 	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
April 29, 2020 	/s/ GAIL K. BOUDREAUX
President and Chief Executive Officer

-- 94 of 97 --

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1. 	I have reviewed this report on Form 10-Q of Anthem, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b) 	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
April 29, 2020 	/s/ JOHN E. GALLINA
Executive Vice President and
Chief Financial Officer

-- 95 of 97 --

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anthem, Inc. (the “Company”) on Form 10-Q for the period ended 	March 31, 2020 	as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
April 29, 2020

-- 96 of 97 --

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anthem, Inc. (the “Company”) on Form 10-Q for the period ended 	March 31, 2020 	as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
April 29, 2020

-- 97 of 97 --